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ABSTRACT
Risk of Newly-diagnosed Depression, Treatment and its Economic Outcomes among
Elderly Medicare Beneficiaries with Incident Breast, Colorectal or Prostate Cancer
Monira Mansour Alwhaibi
Depression is a highly prevalent chronic condition among the elderly cancer survivors. It is
estimated that 5-25% of elderly cancer survivors suffer from depression. Depression co-existing
with cancer is associated with many negative health consequences such as high mortality, poor
health related quality of life and high healthcare utilization and expenditures. However,
depression is treatable with pharmacotherapy, psychotherapy or combination of both. There are
no studies that examine the variations in the risk of depression by cancer types and there are few
studies that examined the rates of depression treatment among elderly with cancer. In addition,
there is lack of evidence on the impact of depression treatment on the economic outcomes of
cancer survivors. To fill the knowledge gap, the three related aims of this dissertation were to:
(1) examine the variations in the risk of depression by cancer types among elderly with incident
breast, colorectal, and prostate cancer; (2) identify the rates of depression treatment and the
factors associated with depression treatment among elderly with newly-diagnosed depression and
incident breast, colorectal and prostate cancer; (3) analyze the impact of depression treatment on
the healthcare expenditures among elderly with newly-diagnosed depression and incident breast,
colorectal and prostate cancer. The study used a retrospective cohort study design, using multiple
years (2002-2011) of the cancer registry data from the Surveillance, Epidemiology and End
Results (SEER) program linked with the Medicare claims data, the American community survey
census-tract files and the Area Health Resource Files. In the first aim, among elderly with
incident breast, colorectal and prostate cancer (N= 53,821), women with colorectal cancer had
28.0% higher risk of newly-diagnosed depression as compared to women with breast cancer;
men with colorectal cancer had 104.0% higher risk of newly-diagnosed depression as compared
to men with prostate cancer. Elderly diagnosed with cancer at an advanced stage had a 61.0%
higher risk of newly-diagnosed depression as compared to those diagnosed with cancer at an
early stage. Elderly with higher number of primary care providers visits had a higher newlydiagnosed depression as compared to those with lower number of primary care providers visits.
In the second aim, among elderly with newly-diagnosed depression and incident breast,
colorectal and prostate cancer (N= 1,673), 45.7% received antidepressants only; 8.8% received
psychotherapy only; 18.4% received combined therapy; and 27.1% received no treatment for
depression. Elderly cancer survivors who received ongoing cancer treatment were less likely to
receive psychotherapy only, or combination therapy. Elderly living in counties with a higher
percentage of psychologists were more likely to receive psychotherapy only, or combination
therapy. In the third aim, among elderly with newly-diagnosed depression and incident breast,
colorectal and prostate cancer (N= 1,502), the average 1-year total healthcare expenditures after
depression diagnosis were higher among those who received depression treatment as compared
to no depression treatment. The associations between depression treatment and the higher
healthcare expenditures were observed across all types of healthcare expenditures (inpatient,
outpatient, prescription drugs, and other expenditures). To summarize, this dissertation found
that there are variations in the risk of newly-diagnosed depression by cancer type. Among cancer
survivors with newly-diagnosed depression, one-quarter of cancer survivors did not receive any
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form of depression treatment; cancer-related factors were associated with depression treatment;
and depression treatment was associated with increase in short-term healthcare expenditures.
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Chapter 1
Introduction
1.1 Background
It is projected that there will be 19 million cancer survivors in the United States (US) by
2024. “A cancer survivor is a person who has been diagnosed with cancer, from the time of
diagnosis throughout his or her life.” (1). Cancer is the disease of the elderly; 63% of cancer
survivors are age 65 years and older (2). Cancer survivors often find the diagnosis of cancer to be
a very stressful life event; they may face a fear of death, changes in physical health, life plans,
work, and social roles and may face some financial concerns (3). As a result, some cancer
survivors may have difficulties adjusting to the diagnosis of cancer and may develop
psychological side effects. Evidence from the literature suggests the psychological effects of a
cancer diagnosis may range from sadness to depressive symptoms to clinical depression,
hereinafter referred to as “depression” (4).
1.1.1 Depression Diagnosis
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V), a depression diagnosis is confirmed if individuals present with at least five symptoms
which persist over a period of at least two weeks (5). These symptoms include: 1) depressed
mood; 2) loss of interest or pleasure in usual activities (anhedonia); 3) weight loss or change in
appetite; 4) change in sleep (insomnia or hypersomnia); 5) change in activity; 6) fatigue/loss of
energy; 7) feelings of guilt/worthlessness; 8) difficulty concentrating or thinking; 9) thoughts of
death or suicide. Depression is present when these symptoms cause clinically significant distress
and impairment in social, occupational or other important areas of functioning (5).
There are different tools to diagnose depression; the gold standard for depression
diagnosis is the Structured Clinical Interview, a clinical interview administered by mental health
1

providers that is based on the symptom criteria for a major depressive disorder in the DSM-IV
(5). However, because the structured clinical interview can be time-consuming and expensive to
administer, epidemiological studies often use depression rating scales with cut-off points to
diagnose depression. Depression rating scales can be administered by trained interviewers or can
be completed by patients (a patient self-report scale). Examples of the scales administered by
trained interviewers include the Hamilton Depression Rating Scale (HDRS) and the
Montgomery-Åsberg Depression Rating Scale. Examples of patient self-report scales include the
Beck Depression Inventory, the Center for Epidemiologic Studies Depression Scale, the Hospital
Anxiety and Depression Scale (HADS), the Geriatric Depression Scale, the Patient Health
Questionnaire, and the Zung Self-rating Depression Scale. These scales are usually used in
Randomized Control Trials (RCTs) as screening tools to identify depression before conducting a
structured clinical interview or as assessment tools for response to depression treatment.
1.1.2 Prevalence of Depression among Cancer Survivors
Using these self-reported scales or physician diagnoses, it has been found that prevalence
rates of depression are higher among cancer survivors as compared to their matched non-cancer
controls (6-8). It is estimated that 10-25% of breast cancer survivors (7,9,10), 8-18% of
colorectal survivors (11,12), and 5-10% of prostate cancer survivors suffer from depression
(13,14). The variability in the prevalence rates of depression within any cancer types is due to
heterogeneous samples, different settings, time periods, and the use of different instruments used
to diagnose depression. Some studies used the structured clinical interview (9) or the
International Classifications of Diseases – 9th edition, Clinical Modification Codes (ICD-9-CM)
diagnostic codes recorded in healthcare claims (11-14). Other studies used self-reported
symptoms scales with cut-off points to diagnose clinical depression, specifically the Hospital
Anxiety and Depression Scale and the Beck Depression Inventory (9,10).
2

1.1.3 Incidence of Depression among Cancer Survivors
While the prevalence of depression among cancer patients is examined extensively in the
literature, studies on the incidence of depression after cancer diagnosis are sparse. Studies that
examined the incidence rate of depression have compared the rate of depression among cancer
survivors to matched non-cancer cohorts (6-8). An observational study using the Surveillance
Epidemiology and End Results (SEER)-Medicare database for the years 1998-2002 examined
the age-race adjusted incidence rate of depression among 51,590 elderly Medicare beneficiaries
(age ≥ 66) with breast cancer (7). This study found a 12-month depression incidence rate was 24
per 1000 person-years after cancer diagnosis. Another study using SEER-Medicare data for the
years 1998-2002 examined the unadjusted incidence rate of depression among 5,087 elderly
Medicare beneficiaries (age ≥ 66) with ovarian cancer (6). This study found a 12-month
depression incidence rate of 65 per 1000 person-years after cancer diagnosis. These studies
followed individuals over varying periods and, therefore, estimated the incidence rate of
depression per 1000 person-years.
1.1.4 Risk Factors for Depression among Cancer Survivors
Cancer-Related Factors
The stage at cancer diagnosis can increase the risk of developing depression, hereinafter
referred to as “newly-diagnosed” depression. A longitudinal study of 500 elderly cancer patients
(age ≥65) receiving chemotherapy found that advanced stage at cancer diagnosis was
significantly associated with depression (β=0.83, SE=0.28, P=0.003) (15). An observational
study using the SEER-Medicare database for the years 1998-2002 among 51,590 elderly
Medicare beneficiaries (age ≥ 66) with breast cancer found that the risk of depression was higher
among women with advanced stage at breast cancer diagnosis as compared to those with earlystage at breast cancer diagnosis (7).
3

Cancer treatment type can affect the risk of developing depression. A study among
women with early-stage breast cancer found that women who received chemotherapy were more
likely to have a probable case of depression (Odds Ratio (OR) = 2.07; 95% CI: 1.18–3.62) as
compared to those who did not receive chemotherapy (16). A prospective study among 64
women with stage I–III breast cancer found a significant association between chemotherapy
treatment and depression (17). Another prospective study among 32 women with stage I-III
breast cancer also found a significant association between chemotherapy treatment and
depression (18). A study among 61 men with prostate cancer found that androgen deprivation
therapy was associated with depression as compared to those who received surgery (19). Another
study among men with prostate cancer found that radiotherapy was associated with depression as
compared to prostatectomy (20). These findings suggest that the risk of developing depression
may depend on the type of treatment received.
Socio-demographic Correlates
Socio-demographic factors can also influence the risk of depression among cancer
survivors. A retrospective cohort study using SEER-Medicare data for elderly Medicare
beneficiaries with localized prostate cancer found that a higher percentage of men who were
white (4.8% vs. 3.5%), unmarried (6.6% vs. 3.9%), had low income (5.4% vs. 3.6%), and lived
in non-metropolitan area (5.5% vs. 4.4%) had diagnosed depression as compared to African
Americans, married, those who had high income or lived in metropolitan areas (14). Among
cancer survivors, older age groups had higher rates of diagnosed depression, as compared to
younger age groups (16-18,21).
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Pre-existing and co-existing chronic conditions
The number and types of pre-existing chronic conditions may also be associated with
depression among cancer survivors. A retrospective cohort study using SEER-Medicare data for
men diagnosed with localized prostate cancer found that men with a higher comorbidity index
had a significantly higher percentage of depression diagnosis as compared to those with a lower
comorbidity index (9.1% vs. 3.4%) (14). Anxiety usually co-exists with depression in cancer
patients. A cross-sectional study of 8,265 adult cancer patients has found that 12.4% of patients
had co-existing anxiety and depression (16).

1.1.5 Negative Health Consequences of Depression among Elderly Cancer Survivors
Mortality
Among cancer survivors, the presence of depression is associated with higher all-cause
mortality (13), cancer-specific mortality (11), and suicide (22). A retrospective cohort study
using SEER-Medicare data for 50,147 elderly Medicare beneficiaries (age ≥ 66) with prostate
cancer examined the association between depression and all-cause mortality (13). The
investigators of this study found that among men with prostate cancer, depression was associated
with 88% greater all-cause mortality (Hazard Ratio (HR), 1.88; 95 % CI: 1.24–2.83) as
compared to those without depression. A retrospective cohort study using the SEER-Medicare
data for 2,199 elderly Medicare beneficiaries (age ≥ 66) with colorectal cancer examined the
association between depression before cancer diagnosis and cancer-specific mortality (11). This
study found that those with a depression diagnosis had 25% greater cancer-specific mortality
(Adjusted Hazard Ratio (AHR) =1.25; 95 % CI: 1.08-1.46) as compared to those without a
depression diagnosis. Depression is also associated with a high risk of suicide among cancer
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survivors. In a retrospective cohort of 667 elderly men (age ≥65) with prostate cancer, it was
found that depression was correlated with the risk of suicide (22).
Health-related Quality of Life (HRQoL)
Depression among cancer survivors has been found to be associated with poor HRQoL
(23). A cross-sectional study among 240 women with breast cancer (mean age 58) found that
those who had depression scored significantly lower on all HRQoL subscales that measured
cognitive, emotional, role, physical, and social functioning, and overall HRQoL compared to
those without depression (23).
Healthcare Utilization and Expenditures
The cost of cancer in the United States is projected to increase from $124 billion to $173
billion by 2020, a 39% increase from 2010 (24). This increase is due to improving survival, new
cancer treatments, and the growth and aging of the population. The financial burden can also
vary by the type of cancer. For example, the estimated cost of cancer was highest for breast
cancer ($16.5 billion), colorectal cancer ($14 billion), followed by prostate cancer ($12 billion)
(25).
Depression among cancer survivors can further increase the financial burden. It is
reported that elderly individuals with cancer and depression had higher healthcare utilization and
expenditures as compared to their counterparts without depression (13,26). A study using SEERMedicare data for the years 1995-2003 examined the association between depression and
healthcare utilization and expenditures among 4,285 elderly (age >66) with prostate cancer and
depression (13). This study found that elderly with both cancer and depression were more likely
to have emergency room visits (Adjusted odds ratio (AOR) =3.5, 95% CI: 3.2-4.3.7), inpatient
visits (AOR=2.8, CI: 2.6-2.9), and outpatient visits (AOR=1.8, CI: 1.7-1.8) as compared to those
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without depression. In addition, this study found that during all phases of cancer (treatment,
follow-up, and terminal phase) prostate cancer patients with depression had higher total
healthcare expenditures as compared to those without depression. For example, during the
treatment phase, depression among elderly with prostate cancer was associated with higher total
health expenditures ($27,500 vs. $20,000) as compared to those without depression. Another
study using claims data for the years 2006-2007 examined the association between depression
and health care expenditures among 11,014 non-elderly military healthcare beneficiaries (ages
18-64) with different types of cancer and newly-diagnosed depression (26). This study found that
those diagnosed with depression had a significantly higher healthcare utilization for inpatient
visits (mean: 3.2 vs. 0.6), outpatient visits (mean: 33.7 vs. 18.7), and medication use (mean: 45.3
vs. 24.5). This study also found that depression among cancer survivors was associated with a
110% increase in total health expenditures ($16,212 vs. $7,728, p-value<0.05) as compared to
those without depression.
1.1.6 Depression and Cancer Treatment
Depression may affect the choice of cancer treatment, which may, in turn, affect cancer
outcomes. A retrospective cohort study using SEER-Medicare data for elderly Medicare
beneficiaries with colorectal cancer found that those with depression were less likely to receive
chemotherapy (AOR= 0.67; 95% CI: 0.48-0.92) as compared to those without depression (11). A
cross-sectional study among 117 women with breast cancer (ages 28-72) found that those with
depression had a significantly lower acceptance for receiving adjuvant chemotherapy as
compared to those without depression (51.3% vs. 92.2%, P<0.0001) (27). An observational study
using SEER-Medicare data among 24,698 elderly women with breast cancer found that women
with depression were more likely to receive non-definitive cancer treatment as compared to those
without a depression diagnosis (AOR= 1.19; 95% CI: 1.06-1.33) (28). A population-based
7

observational study using SEER-Medicare data on men with localized prostate cancer found that
those with pre-existing depression were less likely to undergo definitive treatment (surgery or
radiation) as compared to those without a depression diagnosis (14).

1.1.7 Depression Treatment
Modalities of Depression Treatment
While depression has many negative consequences, it is a treatable chronic illness (3).
Relief from depression can be achieved with either pharmacotherapy, psychotherapy or a
combination of pharmacotherapy and psychotherapy (American Psychiatric Association, 2010).
Pharmacotherapy typically consists of antidepressants such as Selective Serotonin Reuptake
Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic
Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs) and others (mirtazapine,
bupropion) (5). The selection of antidepressant medication depends on concurrent chronic
conditions, the safety and the side-effects profile of the antidepressant, pharmacological
properties (drug interaction) and patient preference.
Depression can also be treated with psychotherapy. Psychotherapy can take different
forms and be provided in group or individual settings. These therapies consist of cognitivebehavioral therapy (CBT), interpersonal therapy, psychodynamic therapy, and problem-solving
therapy (PST) (5). Factors that can affect the choice of using psychotherapy can include the
severity of depression, availability and affordability of psychotherapy, and patient preferences.
Efficacy of Antidepressants in Treating Depression among Elderly
A case needs to be made for the efficacy of depression treatment among the elderly (age
> 65 years) because cancer is often considered the disease of the elderly (2). The median age at
diagnosis is 61 for breast cancer, 69 for colorectal cancer, and 66 for prostate cancer (29).
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However, there is uncertainty about the efficacy of antidepressants in adults 65 years and older
(30,31). A meta-analysis of 6 double-blind RCTs involving 1,840 patients aged 65 years and
older examined the efficacy of antidepressants in treating depression (30). The investigators of
this meta-analysis concluded that there were no statistically significant differences between the
treatment groups and the placebo groups (Relative Risk (RR) = 1.13; 95% CI: 0.93–1.37, p =
0.265). The efficacy of antidepressants in treating depression among adults aged 60 years and
older was also examined in a meta-regression of 34 double-blind RCTs (31). Findings from this
meta-regression revealed that at 12-week follow-up, older age was associated with lower
response to antidepressants.
Efficacy of Antidepressants in Treating Depression among Adult Cancer Survivors
There have been few RCTs that examined the efficacy of antidepressants in treating
depression among cancer survivors. The efficacy of antidepressants in all of these clinical trials
was defined as a reduction in depressive symptoms scores. A 4-week RCT compared mianserin,
a TCA, to a placebo in 73 women with depression and different types of cancer (32). This study
found a significant reduction in depression score from baseline on the HDRS rating scale in the
mianserin group as compared to the placebo at week 4 of depression treatment. A 6-week RCT
among 55 women with both early stage breast cancer and depression compared mianserin to a
placebo (33). This study found a significant reduction in depression score from baseline on the
HDRS rating scale in the mianserin group as compared to the placebo at four and six-week
follow-up periods. A 6-week RCT among 40 women with depression and different types of
cancer assigned them to either fluoxetine or desipramine or placebo (34). The investigators found
a significant reduction in depression score from baseline on the HDRS rating scale in both the
fluoxetine and the desipramine groups as compared to the placebo.
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In contrast, a 5-week RCT among 115 cancer patients with depression and different types
of cancer compared fluoxetine, an SSRI, to a placebo (35). This trial found no significant
reduction in depression scores from baseline on the HADS rating scale between the fluoxetine
group and the placebo. A 6-week RCT among 35 women with breast cancer compared
paroxetine, an SSRI, or desipramine, a TCA, to a placebo (36). The investigators did not find a
significant reduction in depression score from baseline on the HDRS rating scale between the
treatment groups and the placebo. Laoutidis & Mathiak conducted a meta-analysis of six RCTs
that examined the efficacy of antidepressants in patients with cancer (37). Based on this metaanalysis, the investigators found that patients who used antidepressants were 50% more likely to
achieve a therapeutic response compared to the placebo (RR = 1.56, 95% CI: 1.07 – 2.28).
However, these investigators concluded that due to the small number of patients and lack of
clarity in the risk of bias, the findings cannot be used to recommend antidepressant therapy for
treating depression among cancer patients.
In summary, RCTs have shown mixed results on the efficacy of antidepressants among
cancer patients even with the same type of antidepressants. In, addition, there are no studies on
the efficacy of antidepressants in elderly cancer survivors. Even when antidepressant usage was
examined among elderly individuals in general (age ≥ 65), antidepressants were not found to be
efficacious in treating depression among the elderly. As cancer is often diagnosed in the elderly
population (2) and the efficacy of antidepressants among elderly individuals is questionable, one
can conclude that the efficacy of antidepressants among cancer survivors is yet to be established.
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Efficacy of Psychotherapy in Treating Depression among Elderly Individuals
RCTs have shown all types of psychotherapy to be efficacious in the short-term among
individuals aged 50 and older (38). A RCT among 44 elderly (age ≥ 60) individuals with
depression compared CBT versus usual care (39). This study found a significantly lower
percentage of individuals with depressive symptoms in the CBT group as compared to usual care
at the 18 weeks follow-up period (26% vs. 58%, p=0.05). A meta-analysis of 27 RCTs involving
2,245 patients 55 years and older compared psychotherapy treatment to control groups (waitinglist, usual care, attention, supportive therapy, and placebo) (38). This meta-analysis included
different types of psychotherapy with varying observation periods (4 to 26 weeks) and varying
numbers of psychotherapy sessions (4 to 12 sessions). The results from this meta-analysis
revealed that psychotherapy was effective in reducing depression scores as compared to control
groups (Standardized mean differences (SMD): 0.73; 95% CI: 0.51-0.95, p <0.00001). In this
meta-analysis, a subgroup analysis of individuals who were aged 60 and above revealed similar
results. Another meta-analysis of 44 RCTs involving 4,409 patients aged 50 and older compared
psychotherapy to control groups (waiting-list, usual care, attention, supportive therapy,
pharmacotherapy, and placebo) (40). In this meta-analysis, psychotherapy was found to be
effective compared to the control groups (Hedge’s g: 0.64; 95% CI: 0.47-0.80). The abovementioned RCTs and meta-analysis of RCTs indicate that psychotherapy is effective in treating
depression in elderly individuals.

Efficacy of Psychotherapy in Treating Depression among Adult Cancer Survivors
Few RCTs have examined the efficacy of psychotherapy in cancer patients. The most
commonly examined forms of psychotherapy among cancer patients include CBT and supportive
therapy provided in an individual or group setting. A RCT of 45 women with an advanced stage
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of breast cancer and depressive symptoms compared 8-week sessions of individual CBT with
three booster sessions to a waiting-list control (41). The study findings showed a significant
reduction in depression score from baseline on the HDRS rating scale in the CBT group as
compared to a waiting-list control. Another RCT compared group CBT to a waiting-list control
group among 62 women with breast cancer (42). This trial found that patients receiving group
CBT achieved a significantly greater reduction in the depression score from baseline as
compared to the control group. In a RCT of 88 women with breast cancer, women were
randomized to 6-week sessions of group CBT or usual psychosocial care (43). The investigators
found that women in the CBT group had lower rates of depression compared to the control group
at six weeks follow-up (6.5% vs. 10.4%, p<0.05). A RCT involving 458 women with metastatic
breast cancer compared weekly group supportive therapy to no therapy. The study found lower
rates of depression in group supportive therapy as compared to the control group at a six months
follow-up period (18% vs. 40%, p=0.002) (44). A meta-analysis of six RCTs, which involved
1,362 participants with mixed types of cancer, compared psychotherapies (PST, CBT) to control
groups (wait-list, usual care). This meta-analysis found that psychotherapy interventions were
more efficacious than the control groups (45).
To summarize, although studies among elderly, in general, did not specifically focus on
individuals aged 65 and older, all types of psychotherapy have been found to be efficacious in
the short-term among individuals aged 50 and older. In addition, studies among adult cancer
survivors revealed that psychotherapy is efficacious in the short-term. However, none of these
RCTs evaluated the efficacy of psychotherapy among elderly cancer patients.
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Efficacy of Combined Antidepressants and Psychotherapy in Treating Depression among Elderly
There is a limited number of RCTs on the combination of psychotherapy and
antidepressants compared with mono-therapies for the treatment of depression in the elderly. A
12-week RCT of 102 elderly with depression compared combination therapy (desipramine +
CBT) with antidepressant only (desipramine) and CBT only (46). The findings of this trial show
a greater reduction in depressive symptoms for the “combination therapy” group as compared to
antidepressants only. However, there were no differences between combination therapy and CBT
only. A double-blind RCT among 80 ambulatory older adults (age >50) examined the efficacy of
combined IPT and nortriptyline versus a placebo and IPT group for treating bereavement-related
major depressive episodes (47). This study found that the remission rate for nortriptyline plus
IPT was higher than for the placebo plus IPT (69% vs. 29%).

Efficacy of Combined Antidepressants and Psychotherapy in Treating Depression among Cancer
Survivors
There is limited research on the efficacy of combination therapy, with antidepressants
and psychotherapy, in treating depression among cancer patients. To our knowledge, only one
RCT examined the efficacy of combination therapy among cancer survivors in usual care
settings. A RCT of 72 adult cancer patients (non-elderly) with depression has compared a
narrative therapy (NT) plus escitalopram group to a escitalopram plus usual care group (48). This
study found no significant difference in depressive symptoms between the two groups.
The above-mentioned RCTs provide some evidence for the efficacy of combination
therapy as compared to mono-therapy in treating depression among the elderly. However, none
of these studies examined the efficacy of combination therapy in treating depression among
elderly cancer patients, therefore combination therapy’s efficacy is not yet established.
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Clinical Practice Guidelines for Treating Depression in Cancer Survivors
Despite mixed evidence regarding the efficacy of antidepressants and psychotherapy for
treating depression in cancer patients, practice guidelines have been developed for treating
depression in cancer patients (49,50). A guideline was established by the Supportive Care
Guidelines Group from Canada based on a systematic review of the published literature through
June 2005 (50). This guideline recommends antidepressants to cancer patients with moderate to
severe major depression. However, this guideline does not prioritize antidepressants over
psychosocial interventions, nor one antidepressant over another. Another Canadian guideline was
developed in 2010 through a collaboration between the Canadian Partnership against Cancer and
the Canadian Association of Psychosocial Oncology (CAPO) (49). This guideline was adopted
by the American Society of Clinical Oncology (ASCO) in 2014 (51). In this guideline, there is
no recommendation about any antidepressants being better than the other and it recommends that
the selection of antidepressants should be based on side-effect profile, drug interaction, patient
age, and patient preference.
The American Psychiatric Association (APA) guideline recommends treatment of
depression in all adults and includes specific recommendations for the elderly (5). According to
the APA, depression treatment needs to be considered in three phases: an acute phase to attain
remission of symptoms, a continuation phase to prevent a relapse, and a maintenance phase to
prevent a recurrence. This guideline recommended a period of 4-8 weeks to assess the
effectiveness of treatment in the acute phase of treatment. If patients respond to treatment in the
acute phase, then the guideline recommends that they should continue the treatment for 4 to 9
months (continuation phase). A maintenance phase is required to prevent a relapse for patients at
high risk of recurrence such as a family history of depression or residual symptoms.
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Depression Treatment in Real-World Clinical Practice Settings
Depression treatment among cancer survivors has been examined with a few studies. A
cross-sectional study using the Medicare Current Beneficiary Survey (MCBS) from 2000-2005
examined the rate of antidepressant use among 865 elderly (age ≥ 65) with both cancer and
depression. The investigators found that among elderly with both cancer and depression, 57%
received antidepressants only, 19% received psychotherapy with or without antidepressants, and
24% did not receive any depression treatment (52). Another cross-sectional study using the
Medical Expenditures Panel Survey (MEPS) from multiple years, 2006-2008, examined
depression treatment among 528 adults (both elderly and non-elderly) with both cancer and
depression (53). This study estimated that 17% of elderly cancer patients with depression did not
receive any depression treatment (defined as antidepressants with or without psychotherapy).
These studies indicate that no treatment for depression can range from 17% to as high as 24% of
elderly with both cancer and depression.
1.2 Need for the Study
Based on our review of the existing literature on depression among cancer patients,
studies on the incidence of depression after cancer diagnosis are sparse. To date, there have been
only two studies that examined the incidence of depression among cancer survivors (6,7). These
studies suggested that the incidence of depression within 12 months after the cancer diagnosis is
24 per 1000 person-years for women with breast cancer and 65 per 1000 person-years for women
with ovarian cancer. While these studies contributed to the knowledge-base for incidence of
depression among women with breast and ovarian cancer, none of them examined the risk of
developing depression in colorectal and prostate cancer patients, thus, a knowledge-gap exists.
Further, there are no studies that compare the risk of depression among gender-specific cancers
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(women breast cancer vs. women colorectal cancer and men prostate cancer vs. male colorectal
cancer).
There is also a paucity of research on depression treatment in elderly cancer patients with
newly-diagnosed depression after a cancer diagnosis. Only two studies in the United States have
examined depression treatment in elderly cancer patients with a depression diagnosis (52,53).
These studies indicate that no treatment for depression for elderly with both cancer and clinical
depression can range from 17% to as high as 24%. However, these studies were limited to
examining any depression treatment (53) and did not examine treatment with psychotherapy only
(52). In addition, both studies examined depression treatment among elderly with any cancer and
did not distinguish between types of cancer and non of these controlled for cancer related factors
such as stage at cancer diagnosis and cancer treatment. It is unknown how depression is treated
for distinct types of cancer. In addition, the subgroup differences in depression treatment among
elderly with breast, colorectal or prostate cancer is unknown, therefore, a knowledge-gap exists.
Further, there is evidence that depression among cancer patients is associated with
increased financial burden. Studies have shown that depression among cancer patients was
associated with a 37.5% to 110% increase in total health care expenditures as compared to the
expenditures of those without depression (13,26). Depression treatment can be a pathway to
reduce healthcare utilization and expenditures as it has been shown to reduce depressive
symptoms and to improve the quality of life for cancer survivors (54,55). There are no studies
that examined the association between depression treatment and healthcare expenditures among
cancer survivors with newly-diagnosed depression in a usual care setting, thus, a knowledge-gap
exists. Therefore, the current dissertation will address these gaps in knowledge among elderly
cancer survivors with incident breast, colorectal or prostate cancer. The rationale for the
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selection of these cancer types is discussed in the Methods section. The study has the following
specific aims, objectives, and hypotheses.

1.3 Aims, Objectives and Hypothesis
Aim 1
Investigate the risk of newly-diagnosed depression among elderly Medicare beneficiaries
with incident breast, colorectal or prostate cancer.
Objective 1.1
Estimate the rates of newly-diagnosed depression by cancer types (breast vs. female colorectal
and prostate vs. male colorectal cancer) among elderly Medicare beneficiaries who have incident
breast, prostate or colorectal cancer.
Objective 1.2
Examine the risk of newly-diagnosed depression by cancer types (breast vs. female colorectal
and prostate vs. male colorectal cancer), after controlling for other risk factors, among elderly
Medicare beneficiaries who have incident breast, prostate or colorectal cancer.
Hypothesis 1.2
Among cancer patients, women with colorectal cancer will be more likely to be
diagnosed with incident depression as compared to women with breast cancer; men with
colorectal cancer will be more likely to be diagnosed with incident depression as
compared to men with prostate cancer.
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Aim 2
Examine the rates and factors associated with depression treatment among elderly
Medicare beneficiaries with newly-diagnosed depression and incident breast, colorectal or
prostate cancer.
Objective 2.1
Estimate the rates of depression treatment among elderly Medicare beneficiaries with newlydiagnosed depression and incident breast, colorectal or prostate cancer.
Objective 2.2
Examine the predisposing, enabling, need, and external environment factors associated with
depression treatment among elderly Medicare beneficiaries with newly-diagnosed depression
and incident breast, colorectal or prostate cancer.
Hypothesis 2.2
Cancer-related factors will be associated with a lower likelihood to receive depression
treatment.
Aim 3
Examine the association between depression treatment and total healthcare expenditures
among elderly Medicare beneficiaries with newly-diagnosed depression and incident
breast, colorectal or prostate cancer.

Objective 3.1
Estimate total and types of healthcare expenditures by depression treatment categories among
elderly with newly-diagnosed depression and incident breast, colorectal and prostate cancer.
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Objective 3.2
Evaluate the relationship between depression treatment categories and total and types of
healthcare expenditures among elderly with newly-diagnosed depression and incident breast,
colorectal and prostate cancer, after controlling for predisposing, enabling, need, and external
environment factors.
Hypothesis 3.2
The short-term total healthcare expenditures will be higher among elderly who received
depression treatment compared to those who received no treatment.

1.4 Data Source
1.4.1 Surveillance, Epidemiology and End Results (SEER)
The SEER Program is an epidemiologic surveillance system consisting of populationbased tumor registries residing in 18 SEER areas (Atlanta, Connecticut, Detroit, Hawaii, Iowa,
New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles and San JoseMonterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana, New Jersey,
and Greater Georgia) (56). SEER cancer registries collect data on all incident cases of cancer that
occur in persons residing in SEER areas. These data are available in the Patient Entitlement and
Diagnosis Summary File (PEDSF) file which has information on a patient’s demographic
characteristics, cancer type, tumor characteristics, and chemotherapy and radiation therapy
provided within four months of cancer diagnosis.
1.4.2 Medicare
As Medicare is the primary health insurer for the elderly, SEER data have been linked to
Medicare claims. SEER has been linked to Medicare using an algorithm based on the patient first
name, last name, date of birth and social security number. A total of 93% of persons age 65 and
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older in the SEER files has been matched to the Medicare enrollment file (57). Most of Medicare
beneficiaries receive Medicare Part A and B coverage. Part A of the Medicare program covers
the following types of services: inpatient hospitalization, Skilled Nursing Facility (SNF), home
health services following hospital stay (HHA) and hospice care. Part B of the Medicare program
covers the following types of services: physician services, outpatient services, diagnostic tests,
Durable Medical Equipment (DME), emergency room visits, home health care not following a
hospital stay, laboratory services, and other medical services. Medicare program also covers
prescription drugs, Medicare Part D. Medicare data does not include all the claims for the
beneficiaries enrolled under the Health Maintenance Organizations (HMOs) as the organizations
are not required to submit all their services claims to Center for Medicare and Medicaid (CMS).
Medicare claims files consist of inpatient claims (Medicare Provider Analysis and Review
(MEDPAR), outpatient claims (National Claims History (NCH) and Outpatient Claims Files
(OUTSAF)), Durable Medical Equipment (DME), Home Health Agency (HHA) as well as a
prescription drug file (PDESAF). In the current study, this study utilized data from the PEDSF
file linked with MEDPAR, OUTSAF, and NCH, HHA and PDESAF files for the years 2007 to
2012.
1.4.3 American Community Survey (ACS) Estimates from Census
This study used the ACS 2008 to 2012 census tract and census zip code files. These files
were linked to PEDSF files by geographic codes, which included state and county. These files
were used to derive the census tract median household income and education level.
1.4.4 The Area Health Resource File (AHRF)
The AHRF is a publicly available data file provided by Department of Health and Human
Services; it includes county, state and national files (58). The AHRF provides more than 6,000
variables for each of the nation's counties. The AHRF contains information on health facilities,
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health professions, and socioeconomic and environmental characteristics. The AHRF was used
to provide county-level urban/rural continuum codes, percentage of psychologists, and on the
presence of community mental health clinics. The AHRF files were linked to PEDSF files by
geographic codes, which included state and county.
1.5 Rationale for Cancer Selection
This dissertation included breast, colorectal or prostate cancers because they are projected
to be the most common types of cancer by 2024; breast cancer among women (41%), prostate
cancer among men (45%), and colorectal cancer among men and women (8%) (29). In addition,
depression is highly prevalent in these cancer types (9,11-13). In this dissertation, depression
incidence and depression treatment were compared within gender-specific cancers (women
breast vs. women colorectal cancer and men prostate vs. men colorectal cancer).
Depression incidence and depression treatment may not be similar among these types of
cancer due to differences in survival prognosis and stage at the time of cancer diagnosis. With
regard to cancer survival, survival prognosis may affect the risk of developing depression and
depression treatment, and it is well documented that survival rates vary by types of cancer. The
estimated 5-year relative survival rate is 89% for women with breast cancer, 99% for patients
diagnosed with prostate cancer and 65% for patients with colorectal cancer (29). With regard to
the stage at cancer diagnosis, the differences in the stage of cancer at the time of cancer diagnosis
can affect the risk of depression. Danese and colleagues found that the risk of depression among
women with breast cancer was higher among women diagnosed at an advanced stage of cancer
compared to those diagnosed at an early stage of breast cancer (Stage IV: 17% vs. Stage I: 3%)
(7). Colorectal cancer is usually diagnosed at a late stage as compared to breast and prostate
cancer (29). It is plausible that due to competing demands and prioritization, all attention may be
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focused on the treatment of cancers that have lower survival rates and are diagnosed at late stage
rather than on the recognition and management of other co-existing conditions such as
depression.

1.6 Rationale for Selection of Elderly Individuals
This dissertation focused on elderly individuals with breast, colorectal or prostate cancer.
Elderly individuals were selected because cancer is the disease of the elderly; 72% of breast
cancer, 82% of colorectal cancer, and 90% of prostate cancer patients were 60 years and older
(29). In addition, as 97% of the US population aged 65 years and older are covered by Medicare,
which is the US government mandated insurance program, this study used inpatient, outpatient,
prescription drugs claims that were linked to cancer related information from PEDSF file.

1.7 Conceptual Framework
The first aim of the current dissertation adapted the determinants-of-health model by
Marmot and Wilkinson (1999) (59). This model posits that many dimensions affect an
individual’s health or disease/illness (e.g., newly-diagnosed depression). These dimensions are 1)
Individual physical makeup variables included age in years at cancer diagnosis, and
race/ethnicity; 2) Social Support was marital status; 3) Access to care was measured by Primary
Care Physicians (PCP) visit, census-tract median household income, and percentage with less
than high school education level; 4) Health behavior consisted of tobacco use; 5) Psychological
factors included anxiety; 6) Biological risk factors were the stage of cancer at diagnosis and
chronic physical conditions during; 7) Treatment factors included cancer treatment; 8)
Community Resources consisted of the presence or absence of county-level community mental
health clinics (CMHC) and whether the county of residence was designated as health
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professional shortage area (HPSA) for mental health; 8) Geographical location consisted of the
SEER region, and county metro status. To control for changes in patterns of diagnosis over time,
year of cancer diagnosis was also included.
The second and third aim of the current dissertation used the expanded behavioral model
on healthcare utilization, the Andersen Behavioral Model, to help in our selection of variables
that may affect health care utilization (Figure 1) (60). For the second aim, according to this
model, depression treatment (i.e. health services utilization) is a function of: 1) an individual’s
predisposition to utilize the services – predisposing factors (age, race/ethnicity); 2) factors which
enable individuals to use healthcare services – enabling factors (marital status, PCP visits, cancer
type, cancer stage, cancer treatment) 3) an individual’s level of need – need factors (chronic
conditions) and 4) the external environment.
For the third aim, according to this model, healthcare expenditures varies as a function of
1) predisposing factors – age and race; 2) enabling factors: cancer type, cancer stage, cancer
treatment, marital status and PCP visits; 3) need factors – depression treatment, the number of
chronic physical and mental health conditions; and 4) the external environment: SEER region
and year of cancer diagnosis.
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Figure 1.1: Conceptual Framework: Adapted Andersen Behavioral Model

Predisposing factors
Demographics: age, and race/ethnicity
Enabling factors
Marital status, and census tract
socioeconomic factors (median household
income, % with college education)

Aim2: Dependent
Variable
Depression
Treatment

Need factors
Chronic physical conditions, mental
conditions, Cancer type, cancer stage, cancer
treatment
External environment factors
SEER region, area of residence (metro/nonmetro), county level % of psychologists and
community mental health centers
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STRUCTURE OF THIS DISSERTATION
The current dissertation was organized as follows: Chapter One reviews the current literature on
depression diagnosis among elderly with cancer and provides a justification for the aims of the
current dissertation. Furthermore, Chapter One describes the data sources, provides the rationale
for the selection of cancer types and the conceptual frameworks that guide the selection of
variables in the current dissertation. The methods to conduct the studies of the current
dissertation are described in each chapter. Chapter Two focuses on the risk of newly-diagnosed
depression among elderly with incident cancer; Chapter Three focuses on the rates and factors
associated with depression treatment among elderly with newly-diagnosed depression and
incident cancer; Chapter Four focuses on the association between depression treatment and shortterm healthcare expenditures among elderly with newly-diagnosed depression and incident
cancer. Finally, Chapter Five includes a summary of findings, implications, strengths and
limitations and a conclusion from all the findings from the studies of the current dissertation.
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Chapter 2
Cancer Types and the Risk of Newly-Diagnosed Depression among Elderly
Medicare Beneficiaries with Incident Breast, Colorectal and Prostate Cancer
2.1 Abstract
Purpose
Elderly individuals (age > 65 years) with cancer are at high risk for newly-diagnosed depression
after cancer diagnosis. It is not known whether the risk of newly-diagnosed depression varies by
cancer type. Therefore, this study examined the variations in the risk of newly-diagnosed
depression by cancer types among elderly individuals with cancer.
Patients and Methods
This study utilized a retrospective cohort study design and used data from the linked
Surveillance, Epidemiology and End Results (SEER)-Medicare files. Elderly individuals (age >
65 years) with incident breast, colorectal, and prostate cancer diagnosed between 2007 and 2011
(N = 53,821) were followed for 12 months after cancer diagnosis. The risk of newly-diagnosed
depression after cancer diagnosis was identified using the International Classification of
Diseases, 9th Edition, Clinical Modification (ICD-9-CM) Codes. Complementary log-log
regression was used to examine the association between cancer types and the risk of newlydiagnosed depression after adjusting for other risk factors for depression.
Results
This study found a significantly higher percentage of newly-diagnosed depression among women
with colorectal cancer as compared to women with breast cancer (5.8% vs. 3.9%), and among
men with colorectal cancer as compared to men with prostate cancer (3.4% vs. 1.6%). In the
adjusted analysis, women with colorectal cancer had 28.0% higher risk of newly-diagnosed
depression as compared to women with breast cancer (Adjusted Risk Ratio (ARR) = 1.28
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[95%CI, 1.12-1.46]) and men with colorectal cancer had 106.0% higher risk of newly-diagnosed
depression as compared to men with prostate cancer (ARR =2.06 [95% CI, 1.65-2.58]).
Conclusion
The study findings identified cancer types with a high risk of newly-diagnosed depression after
cancer diagnosis who might benefit from routine depression screening and monitoring to help in
early detection and treatment of depression.
Keywords: Cancer, oncology, incident, depression, risk, Medicare.
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2.2 Introduction
Depression is a highly prevalent mental health condition among elderly cancer survivors.
It is estimated that 5-25% of cancer survivors suffer from depression (1-5). Further, the risk of
newly-diagnosed depression is higher among cancer survivors when compared to age-sex
matched non-cancer cohorts, as two retrospective studies have shown (6,7). One study using the
Surveillance Epidemiology and End Results (SEER)-Medicare data found that women with
breast cancer had 58% higher risk of newly-diagnosed depression within a year after cancer
diagnosis as compared to their matched non-cancer counterparts (Adjusted Risk Ratio
(ARR)=1.58; 95%CI, 0.84-3.0) (6). A second study, among adults with different cancer types
found that men with colorectal cancer had 67% higher risk of newly-diagnosed depression as
compared to their age-sex matched non-cancer cohort (Risk Ratio (RR)=1.16; 95% CI, 0.901.51) (7).
The risk of newly-diagnosed depression maybe higher among some cancer types as
compared to others due to differences in survival prognosis and stage at cancer diagnosis (6,8).
The estimated 5-year relative survival rate is 65% for individuals with colorectal cancer as
compared to 89% for women with breast cancer and 99% for men with prostate cancer (8).
Danese and colleagues found that elderly women with breast cancer diagnosed at an advanced
stage (stage IV) had a higher risk of newly-diagnosed depression as compared to those diagnosed
at an early stage (Stage I) (RR= 5.03, 95%CI = 3.45-7.35) (6). Colorectal cancer is more likely to
be diagnosed at an advanced stage and to have a poor survival prognosis as compared to breast
and prostate cancers (6,8). Therefore, colorectal cancer patients may have a higher risk of
newly-diagnosed depression as compared to those with breast or prostate cancer.
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Although the risk of newly-diagnosed depression may vary by cancer type, there is a
paucity of research on the variations in the risk of newly-diagnosed depression by cancer type.
Identifying cancer survivors, who are at high risk of newly-diagnosed depression, is important
because depression can negatively affect the health-related quality of life (HRQoL) and survival
after cancer diagnosis (1,3,9). Therefore, the objective of this study was to examine the
variations in the risk of newly-diagnosed depression by cancer types among elderly Medicare
beneficiaries with incident breast, colorectal and prostate cancer. These cancers were selected
because they are projected to be the most common cancer types by 2024 and in which depression
is highly prevalent (8). This study evaluated the risk of newly-diagnosed depression by cancer
types with the following comparisons: women with breast cancer compared to women with
colorectal and men with prostate cancer compared to men with colorectal cancer.
2.3 Conceptual Framework
This study adapted the determinants-of-health model by Marmot and Wilkinson (1999)
(10). This model posits that many dimensions affect an individual’s health or disease/illness
(e.g., newly-diagnosed depression). These dimensions are an individual’s physical make-up,
social support, access to care, health behaviors, psychological factors, biological risk factors,
treatment factors, community resources, and geographical region.
2.4 Methods
2.4.1 Data Sources
The current study linked data from several sources including the SEER-Medicare linked
database, ACS estimates from census, and the AHRF files. The detailed description of the data
sources are provided in Chapter 1.
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2.4.2 Study Design
This study utilized a retrospective cohort study design with a baseline and follow-up
period. It considered the date of cancer diagnosis as the index date. This study defined the 12
months before the index date as the baseline period and the 12 months after index date as the
follow-up period.
2.4.3 Study population
Identification of Cancer Survivors
The study population composed of elderly cancer patients, age 66 years and older who
were diagnosed with primary only incident breast, colorectal, and prostate cancer between 2007
and 2011. An age of 66 years and above was imposed to allow 12-month baseline period before
cancer diagnosis. The cancer types (breast, colorectal and prostate cancer) were identified using
the primary site variable and the International Classification of Diseases for Oncology, 3rd
Edition (ICD-O-3) histology codes.
Depression-free Individuals at Cancer Diagnosis
This study identified a depression-free cohort among individuals with incident cancer. To
ensure that the incident cancer cases were depression free, a validated criteria from the National
Committee for Quality Assurance (NCQA) was used (13). According to the NCQA, an
individual is considered to be depression-free at index date, if he or she did not receive
antidepressants 90 days before the index date (i.e. date of cancer diagnosis) or did not have any
depression diagnosis 120 days before the index date.
Other inclusion/exclusion criteria
This study required that all individuals have continuous enrollment in Medicare part A, B
and no enrollment in managed care plans during the baseline and follow-up periods. To identify
antidepressants 90 days before the index date, this study also required that individuals have
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continuous enrollment in Medicare part D three months before cancer diagnosis. This study
excluded individuals with an unknown stage at diagnosis or those diagnosed through autopsy or
death certificate, and those who died during the follow-up period of 12 months. Appendix 2.1
demonstrates the analytical population selection process.
2.4.4 Dependent Variable: Newly-diagnosed Depression (Yes/No)
The dependent variable was newly-diagnosed depression after cancer diagnosis (newlydiagnosed depression) in breast, colorectal and prostate cancer survivors. To identify depression
diagnosis, a validated algorithm developed by the Centers for Medicare and Medicaid Services
(CMS) Chronic Conditions Data Warehouse (CCW) was used (14). Individuals with at least one
inpatient visit or one outpatient visit with depression diagnosis during the 12 month follow-up
period were classified as having a newly-diagnosed depression. This study identified depression
diagnosis using the International Classifications of Diseases – 9th edition, Clinical Modification
Codes (ICD-9-CM). The ICD-9-CM codes were: 296.2 , 296.3, 298.0, 300.4, 309.1, and 311.0.
These codes are widely used to identify depression diagnoses among Medicare beneficiaries
(1,15,16).
2.4.5 Key Independent Variable
This study selected the independent variables based on the Determinants of Health
Model. The key independent variable was cancer types which is considered a biological risk
factor. Cancer types were: women with breast cancer, women with colorectal cancer, men with
colorectal cancer and men with prostate cancer.
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2.4.6 Other Independent Variables
Individual physical makeup variables included age in years at cancer diagnosis (66-69,
70-74, 75-79, >=80), and race (White, African American, Hispanic, and others). Social Support
included marital status (married, divorced/separated/widow and never married). Access to care
was measured by Primary Care Physicians (PCP) visit quartiles during 12 months before cancer
diagnosis, census-tract median household income quartiles, and percentage with less than high
school education level quartiles. Health behavior consisted of tobacco use in the baseline period.
Psychological factors included the presence of anxiety during the baseline period. Biological risk
factors were: the stage of cancer at diagnosis (based the American Joint Committee on Cancer
(AJCC) grouped staging) and chronic physical conditions during the baseline period. The
chronic conditions categories included: cardiovascular disease (heart disease (cardiac arrythmia,
coronary heart disease, congestive heart faliure), diabetes, hyperlipidemia, hypertension, stroke),
respiratory disease (asthma, chronic obstructive pulmonary disease), and musculoskeletal disease
(arthritis, and osteoporosis) (17). These conditions were selected based on the Multiple Chronic
Conditions working group framework for research, planning, programs and policy purposes (17).
These conditions were identified based on a validated algorithm developed by the CMS Chronic
Conditions Data Warehouse (14); individuals had at least one inpatient visit or two outpatient
visits during the baseline period. Treatment factors included cancer treatment during the six
months after cancer diagnosis which included chemotherapy, radiation therapy, hormone
therapy, and surgery. Cancer treatment was identified from claims data using the ICD-9-CM,
Health Healthcare Common Procedure Coding System (HCPCS) and the Common Procedural
Terminology (CPT) codes. Community Resources consisted of the presence or absence of
county-level community mental health clinics (CMHC) and whether the county of residence was
designated as health professional shortage area (HPSA) for mental health. Geographical location
36

consisted of the SEER region (Northeast, South, North-central, West), and county metro status
(metro/non-metro) which was defined using 2013 urban/rural continuum codes from the United
States Department of Agriculture’s Economic Research Service. To control for changes in
patterns of diagnosis over time, year of cancer diagnosis was also included as one of the
independent variables.
2.5 Statistical Analysis
This study used chi-square tests to test the significance of unadjusted differences in
baseline characteristics and newly-diagnosed depression. A complementary log-log regressions
analysis were used to examine the adjusted associations between cancer types and the risk of
newly-diagnosed depression with four different models. In model I, only cancer types was
included without controlling for other factors. Model II controlled for individual physical makeup (e.g., age, race) and social support. Model III additionally controlled for access to care, health
behaviors, biological risk factors, and psychological factors. Model 4 additionally controlled for
treatment factors, county-level community resources, geographical region, and the year at cancer
diagnosis. All statistical analyses were carried out in SAS 9.4 (SAS Institute Inc., Cary, NC).
2.6 RESULTS
2.6.1 Characteristics of the study population
The study population consisted of 53,821 elderly fee-for-service Medicare beneficiaries
with incident breast, colorectal, and prostate cancer who were depression-free at the time of
cancer diagnosis. In the study populations, 36.4% were women with breast cancer; 12.5% were
women with colorectal cancer; 9.5% were men with colorectal cancer, and 41.6% were men with
prostate cancer (data not shown in tabular form). The majority of the study population were
White (80.7%), married (52.5%). Eighty-one percent of the counties were metro areas, 51.0% of
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the counties had a shortage of mental health professionals and 48.9% did not have community
mental health centers.
2.6.2 Cancer types and newly-diagnosed depression
Overall, 3.3% of elderly Medicare with breast, colorectal and prostate cancer had newlydiagnosed depression during the follow-up year. A chi-square analysis showed that newlydiagnosed depression rates significantly differed by cancer types (P<0.001) (Table 2). This study
found a significantly higher percentage of newly-diagnosed depression among women with
colorectal cancer as compared to women with breast cancer (5.8% vs. 3.9%), and among men
with colorectal cancer as compared to men with prostate cancer (3.4% vs. 1.6%).
Tables 3 displays the risk ratios (RR) and adjusted RR (ARR) of newly-diagnosed
depression by cancer types from multivariable complementary log-log regression analyses. In
model 1, which included only cancer types, women with colorectal cancer had a 53% higher risk
of newly-diagnosed depression (RR= 1.53 [95%CI, 1.36-1.73]) as compared to women with
breast cancer; men with colorectal cancer had a 111% higher risk of newly-diagnosed
depression(ARR= 2.11 [95% CI, 1.76-2.53]) as compared to men with prostate cancer. This
association between cancer types and the risk of newly-diagnosed depression persisted in Models
II to IV. Even after controlling for all the risk factors and the year at cancer diagnosis in the final
model, women with colorectal cancer had 28% higher risk of newly-diagnosed depression (ARR
= 1.28, 95%CI, 1.12-1.46) as compared to women with breast cancer. Men with colorectal cancer
had a 106% higher risk of newly-diagnosed depression (ARR = 2.06, 95% CI, 1.65-2.58) as
compared to men with prostate cancer.
2.6.3 Sex and newly-diagnosed depression
This study found a significantly higher percentage of newly-diagnosed depression among
women with colorectal cancer as compared to men with colorectal cancer (5.8% vs. 3.4%).
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Tables 4 displays the RR and ARR of newly-diagnosed depression by sex. After controlling for
all the risk factors and the year at cancer diagnosis, women with colorectal cancer had a 52%
higher risk of newly-diagnosed depression as compared to men with colorectal cancer (ARR=
1.52 [95%CI, 1.26-1.83]).
Cancer stage and newly-diagnosed depression
This study found that cancer survivors diagnosed at stage II had 22% higher risk of
newly-diagnosed depression as compared to those diagnosed at stage I (ARR= 1.22 [95%CI,
1.06-1.40]). Cancer survivors diagnosed at stage III had 41% higher risk of newly-diagnosed
depression as compared to those diagnosed at stage I (ARR= 1.41 [95%CI, 1.19-1.68]). This
study also found that cancer survivors diagnosed at stage IV had 63% higher risk of newlydiagnosed depression as compared to those diagnosed at stage I (ARR= 1.63 [95%CI, 1.312.03]). The RR and ARR of newly-diagnosed depression by other variables are displayed in
Appendix 1.1.
2.7 Discussion
This is the first study to date that has evaluated the relationship between cancer types and
the risk of newly-diagnosed depression after cancer diagnosis among elderly individuals with
incident breast, colorectal and prostate cancer. In our study, the rate of newly-diagnosed
depression was highest (5.8%) among women with colorectal cancer and lowest (1.6%) among
men with prostate cancer. The rate of newly-diagnosed depression among women with breast
cancer was 3.9% in our study. This rate is higher than the one estimate (2.4%) available from the
published literature (6). The higher incidence of depression among women with breast cancer in
our study may be due to differences in observation years as it has been reported that the
percentage of diagnosed depression among elderly Medicare beneficiaries increased over time
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(18). While Danese and colleague used data from 1998 through 2002, the current study utilized
data from 2007 through 2012 (6). No other studies have examined the incidence of depression
among patients with prostate and colorectal cancer. Therefore, the incidence of depression for
these cancer types found in our study were not compared to estimates from other studies.
This study found that the risk of newly-diagnosed depression varied by cancer type.
Women with colorectal cancer had a higher risk of newly-diagnosed depression as compared to
women with breast cancer, even after adjustments for a comprehensive list of risk factors.
Similarly, men with colorectal cancer had a higher risk of newly-diagnosed depression as
compared to men with prostate cancer. These findings were robust in different model
specifications and they provide new evidence on the variable risk of depression by cancer type.
As stated in the introduction, it is plausible that poor survival prognosis and late stage at cancer
diagnosis may have increased the risk of depression among colorectal cancer survivors. For
example, in the current study, women and men colorectal cancer survivors were more likely to
be diagnosed at an advanced stage as compared to women with breast cancer and men with
prostate cancer. In multivariable analyses, advanced stage at cancer diagnosis was associated
with higher risk of newly-diagnosed depression as compared to early-stage at cancer diagnosis.
This finding is consistent with prior published studies that documented that advanced stage at
cancer diagnosis is associated with high risk of depression (6,19). This study also found that
women with colorectal cancer had 52% higher risk of newly-diagnosed depression as compared
to men with colorectal cancer. This finding confirmed sex differences in the risk of depression
which have been documented in the previous literature (18).
Clinical practice and policy implications
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Findings from our study have clinical practice and policy implications. Our findings
suggest that oncologists and other healthcare providers may need to screen for depression,
especially individuals with colorectal cancer and those who are diagnosed with an advanced
cancer stage. Indeed, the American Society of Clinical Oncology guideline recommends
screening for depression regardless of cancer types or stage at cancer diagnosis.(20) Cancer is a
dominant condition and most of the care is usually directed towards treating cancer, therefore,
such screening is important to diagnose depression before it becomes severe. It is reported that,
as compared to non-cancer patients, cancer patients who were screened for depression often
exhibited severe depressive symptoms (21); for these individuals early screening for depression
is needed. Screening should occur not only in the oncology setting but also in the primary care
setting, as Medicare provides reimbursement for annual screenings for depression in primary
care settings (22). Our findings indicate that patients who visited a primary care providers have a
higher incidence of depression diagnosis. Therefore, it is important for cancer survivors to
continue visits to their primary care physicians. A national survey of physicians conducted by the
Cancer Care Outcomes Research and Surveillance Consortium has shown that PCPs are more
involved in detection and treatment of depression in cancer patients as compared to oncologists
(50% vs. 18%) (23). Therefore, coordinated care between oncologists and primary care providers
is needed so that oncologists can refer cancer patients to primary care providers for depression
screening.
Study strengths and limitations
This study’s findings need to be interpreted in the context of its advantages and
limitations. One advantage is that this study used linked cancer registry and claims data in which
a large cohort of patients were followed across a variety of health providers. Another advantage
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is that this study has also controlled for a comprehensive list of factors, including cancer stage
and cancer treatment, that may affect the risk of newly-diagnosed depression. A third advantage
is that the availability of cancer diagnosis dates enabled us to identify newly-diagnosed
depression. This study also has some limitations. As the study population was restricted to feefor-service Medicare beneficiaries and those residing in SEER regions, the study findings are not
generalizable to all Medicare beneficiaries. It is plausible that depression may be underrecognized and the rate of newly-diagnosed depression may have been underestimated. While
many variables that may be associated with the risk of newly-diagnosed depression were
captured, some important variables such as family history of depression, obesity, and physical
activity were lacking.
2.8 Conclusion
This study has provided new evidence that there is variation in the risk of newlydiagnosed depression by cancer type. It identified cancer survivors who are more likely to suffer
from depression after cancer diagnosis. Healthcare providers of cancer survivors may need to
screen routinely individuals at high risk for depression, specifically those with colorectal cancer
and those with an advanced stage of cancer at diagnosis.
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Table 2.1
Selected Characteristics of the Study Population by Cancer Types
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer
SEER-Medicare database 2007-2012
Women
Men
Prostate
Breast Cancer Colorectal
Colorectal
Cancer
N

%

N

%

N

%

N

%

chisq

sig

3104.2

***

283.1

***

8300.9

***

352.9

***

99.2

***

270.3

***

Individual Physical Make-up
Age in years
66-69 years

4,768

34.0

1,042

7.4

1,171

8.4

7,026

50.2

70-74 years

5,229

33.1

1,389

8.8

1,434

9.1

7,739

49.0

75-79 years

4,199

37.2

1,439

12.8

1,100

9.8

4,538

40.2

80 years or older

5,382

42.2

2,877

22.6

1,389

10.9

3,099

24.3

Race
White

16,358

37.7

5,304

12.2

3,986

9.2

17,732

40.9

AA

1,627

32.7

719

14.5

374

7.5

2,253

45.3

Others

1,593

29.1

724

13.2

734

13.4

2,417

44.2

Social Support
Marital Status
Married

8,126

28.8

2,152

7.6

3,309

11.7

14,663

51.9

Never married

1,799

37.4

625

13.0

567

11.8

1,820

37.8

Sep/div/wid

8,719

54.1

3,625

22.5

972

6.0

2,800

17.4

934

20.1

345

7.4

246

5.3

3,119

67.2

Unknown

Access to care
Primary care visits
Quartile 1 (Low)

2,636

33.9

844

10.8

865

11.1

3,440

44.2

Quartile 2

1,929

35.2

527

9.6

513

9.4

2,516

45.9

Quartile 3

8,242

40.0

2,474

12.0

1,890

9.2

7,986

38.8

Quartile 4 (High)

6,771

33.9

2,902

14.5

1,826

9.1

8,460

42.4

Health behaviors
Tobacco Use
Yes
No

514

27.0

213

11.2

244

12.8

931

48.9

19,064

36.7

6,534

12.6

4,850

9.3

21,471

41.4

Psychological factors
Anxiety-PTSD
Yes
No

1,159

48.1

414

17.2

170

7.0

669

27.7

18,419

35.8

6,333

12.3

4,924

9.6

21,733

42.3
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Table 2.1
Selected Characteristics of the Study Population by Cancer Types
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer
SEER-Medicare database 2007-2012
Women
Men
Prostate
Breast Cancer Colorectal
Colorectal
Cancer
N

%

N

%

N

%

N

%

chisq

sig

Biological Risk Factors
Cancer Stage
Stage 0

3,441

78.8

520

11.9

407

9.3

0

0.0

Stage I

8,912

73.4

1,856

15.3

1,331

11.0

39

0.3

Stage II

5,157

18.2

2,070

7.3

1,483

5.2

19,638

69.3

Stage III

1,453

24.5

1,735

29.2

1,322

22.3

1,431

24.1

Stage IV

615

20.3

566

18.7

551

18.2

1,294

42.8

Cardiovascular
Yes
No
Musculoskeletal
Yes
No
Respiratory
Yes
No

15,461

36.0

5,552

12.9

4,107

9.6

17,868

41.6

4,117

38.0

1,195

11.0

987

9.1

4,534

41.9

5,282

47.9

1,884

17.1

726

6.6

3,134

28.4

14,296

33.4

4,863

11.4

4,368

10.2

19,268

45.0

2,126

34.7

945

15.4

699

11.4

2,349

38.4

17,452

36.6

5,802

12.2

4,395

9.2

20,053

42.0

26141.0

***

36.4

***

1437.7

***

97.0

***

1028.3

***

4610.0

***

23164.3

***

Treatment factors
Chemotherapy
Yes
No
Radiation therapy
Yes

3,884

26.6

1,674

11.4

1,601

10.9

7,469

51.1

15,694

40.0

5,073

12.9

3,493

8.9

14,933

38.1

9,193

46.0

600

3.0

686

3.4

9,517

47.6

No

10,385

30.7

6,147

18.2

4,408

13.0

12,885

38.1

Surgery
Yes

18,193

53.8

5,779

17.1

4,131

12.2

5,723

16.9

No

1,385

6.9

968

4.8

963

4.8

16,679

83.4

Community Resources
CMHC
Yes
No
HPSA
No shortage

5.5
10,030

36.5

3,496

12.7

2,648

9.6

11,332

41.2

9,548

36.3

3,251

12.4

2,446

9.3

11,070

42.1
57.3

1,871

36.7

677

13.3

477

9.4

2,075

40.7

Whole county

9,693

35.3

3,319

12.1

2,736

10.0

11,700

42.6

Part county

8,014

37.7

2,751

12.9

1,881

8.8

8,627

40.6
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Table 2.1
Selected Characteristics of the Study Population by Cancer Types
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer
SEER-Medicare database 2007-2012
Women
Men
Prostate
Breast Cancer Colorectal
Colorectal
Cancer
N

%

N

%

N

%

N

%

chisq

sig

181.4

***

Geographical Location
Region
Northeast

3,852

37.7

1,515

14.8

942

9.2

3,919

38.3

South

5,003

36.9

1,733

12.8

1,312

9.7

5,516

40.7

North-central

2,603

36.8

987

13.9

627

8.9

2,863

40.4

West

8,120

35.4

2,512

10.9

2,213

9.6

10,104

44.0

Metro status
Metro

15,947

36.5

5,460

12.5

4,056

9.3

18,196

41.7

Non-metro

3,631

35.7

1,287

12.7

1,038

10.2

4,206

41.4

Cancer diagnosis year
2007

9.2

31.901
2,876

34.9

1,068

13.0

797

9.7

3,495

42.4

2008

3,916

35.2

1,433

12.9

1,110

10.0

4,655

41.9

2009

4,091

36.6

1,443

12.9

1,006

9.0

4,627

41.4

2010

4,208

37.2

1,372

12.1

1,065

9.4

4,666

41.3

2011

4,487

37.4

1,431

11.9

1,116

9.3

4,959

41.3

*

**

Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive
during the observation period. Asterisks represent significant differences in study population characteristics by
breast, colorectal and prostate cancer, derived from chi-square statistics.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
AA: African American; CMHC: Community Mental Health Center; HH: household; HS: High school; HPSA: health
professional shortage area; LT: less than; SEER: Surveillance Epidemiology and End Results; Sep/div/wid:
Separated/Divorced/Widowed.
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Table 2.2
Number and Percentage of Newly-Diagnosed Depression by Cancer Types and Treatment
Characteristics Elderly Fee-for-service Medicare beneficiaries with Incident Breast,
colorectal, and Prostate Cancer
SEER-Medicare Database, 2007-2012
Depression
No Depression
Sig
N
%
N
%
Chisq
365.7
***
Cancer types
Women Breast Cancer
755
3.9
18,823
96.1
Women Colorectal Cancer
394
5.8
6,353
94.2
Men Colorectal Cancer
173
3.4
4,921
96.6
Men Prostate Cancer
364
1.6
22,038
98.4
95.8
***
Stage at cancer diagnosis
Stage 0
154
9.1
4,214
8.1
Stage I
433 25.7
11,705
22.5
Stage II
705 41.8
27,643
53.0
Stage III
262 15.5
5,679
10.9
Stage IV
132
7.8
2,894
5.6
0.1
Chemotherapy
Yes
454 26.9
14,174
27.2
No
1,232 73.1
37,961
72.8
49.5
***
Radiation therapy
Yes
489 29.0
19,507
37.4
No
1,197 71.0
32,628
62.6
110.6
***
Surgery
Yes
1,265 75.0
32,561
62.5
No
421 25.0
19,574
37.5

Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive
during the observation period. Asterisks represent significant differences in newly-diagnosed depression by cancer
types, derived from chi-square tests.

*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
SEER: Surveillance Epidemiology and End Results.
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Table 2.3
Adjusted Risk Ratios and 95% Confidence Intervals (CI) of Cancer Types from Complementary Log-Log
Regression on Newly-Diagnosed Depression
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer
SEER-Medicare database, 2007-2012
Model 1: Included the types of cancer without adjustment
Cancer types

RR

95%CI

Reference group = Women Breast Cancer
Women Colorectal Cancer
1.53 [ 1.36 , 1.73]
Men Colorectal Cancer
0.88 [ 0.74 , 1.04]
Men Prostate Cancer
0.42 [ 0.37 , 0.47]

Sig
***
***

RR

Reference group = Men Prostate Cancer
Women Breast Cancer
2.29 [ 1.97 , 2.67]
Women Colorectal Cancer
3.10 [ 2.62 , 3.66]
Men Colorectal Cancer
2.12 [ 1.74 , 2.57]

ARR
95%CI
Sig
Model 2: Adjusted for Individual Physical Make-up and access to care
Women Colorectal Cancer
Men Colorectal Cancer
Men Prostate Cancer

1.49
0.98
0.46

[ 1.32 , 1.69]
[ 0.83 , 1.16]
[ 0.40 , 0.53]

***
***

95%CI

Women Breast Cancer
Women Colorectal Cancer
Men Colorectal Cancer

Sig
***
***
***

ARR

95%CI

Sig

2.17
3.23
2.12

[ 1.90 , 2.47]
[ 2.77 , 3.77]
[ 1.77 , 2.55]

***
***
***

Model 3 Adjusted for cancer type, individual physical make-up and access to care characteristics, health behaviors, and
biological risk factors
Women Colorectal Cancer
Men Colorectal Cancer
Men Prostate Cancer

1.35
0.92
0.44

[ 1.19 , 1.54]
[ 0.78 , 1.10]
[ 0.37 , 0.51]

***
***

Women Breast Cancer
Women Colorectal Cancer
Men Colorectal Cancer

2.33
3.14
2.06

[ 2.00 , 2.72]
[ 2.66 , 3.72]
[ 1.70 , 2.51]

***
***
***

Model 4: Adjusted for cancer type, individual physical make-up and access to care characteristics, health behaviors, and
biological risk factors, treatment factors, community resources, geographical location, and year at cancer diagnosis
Women Colorectal Cancer
Men Colorectal Cancer
Men Prostate Cancer

1.28
0.88
0.43

[ 1.12 , 1.46]
[ 0.73 , 1.05]
[ 0.36 , 0.51]

***
***

Women Breast Cancer
Women Colorectal Cancer
Men Colorectal Cancer

2.33
2.98
2.04

[ 1.95 , 2.78]
[ 2.47 , 3.60]
[ 1.65 , 2.51]

Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive
during the observation period. Asterisks represent significant differences in newly-diagnosed depression by cancer
types, derived from complementary log-log regression.
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05.
ARR: Adjusted Risk Ratio; RR: Risk Ratio; SEER: Surveillance Epidemiology and End Results.
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***
***
***

Table 2.4
Sex Differences in Newly-Diagnosed Depression Adjusted Risk Ratios and 95% Confidence
Intervals of Cancer Types from Complementary Log-Log Regression
on Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident
Breast, colorectal, and Prostate Cancer
SEER-Medicare Database, 2007-2012
Reference group= Men Colorectal Cancer
Model 1
Adjusted only for cancer types
Reference Group = Men Colorectal Cancer
Cancer types
RR
95%CI
Sig
Women Breast Cancer
1.14 [ 0.96 , 1.34]
Women Colorectal Cancer
***
1.74 [ 1.46 , 2.08]
Men Prostate Cancer
0.47 [ 0.40 , 0.57]
***
ARR
95%CI
Sig
Model 2
Adjusted for cancer types, individual physical make-up and access to care characteristics
Women Breast Cancer
1.02 [ 0.86 , 1.21]
Women Colorectal Cancer
***
1.52 [ 1.27 , 1.83]
Men Prostate Cancer
0.47 [ 0.39 , 0.57]
***
Model 3
Adjusted for cancer types, individual physical make-up and access to care characteristics, health
behaviors, and biological risk factors
Women Breast Cancer
1.13 [ 0.95 , 1.35]
Women Colorectal Cancer
***
1.52 [ 1.27 , 1.83]
Men Prostate Cancer
0.48 [ 0.40 , 0.59]
***
Model 4
Adjusted for cancer types, individual physical make-up and access to care characteristics, health
behaviors, and biological risk factors, treatment factors, community resources, geographical location,
and year of cancer diagnosis
Women Breast Cancer
1.14 [ 0.96 , 1.36]
Women Colorectal Cancer
***
1.46 [ 1.22 , 1.76]
Men Prostate Cancer
0.49 [ 0.40 , 0.61]
***

Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive
during the observation period. Asterisks represent significant differences in newly-diagnosed depression by cancer
types, derived from complementary log-log regression.
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05.
ARR: Adjusted Risk Ratio; RR: Risk Ratio; SEER: Surveillance Epidemiology and End Results.
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Appendix 2.1
Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log Regression on
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and
Prostate Cancer SEER-Medicare Database, 2007-2012
ARR
Cancer types
Women Breast Cancer
(Ref.)
Women colorectal cancer
Men colorectal cancer
Men Prostate Cancer
Age
66-69
70-74
75-79
>=80 (Ref.)
Race
White (Ref.)
African American
Hispanic
Others
Unknown
Married (Ref.)
Never married
Sep/div/wid
Unknown
Median HH income
Quartile 1 (Low)
Quartile 2
Quartile 3
Quartile 4 (High)
% LT HS education
Quartile 1 (Low)
Quartile 2
Quartile 3
Quartile 4 (High)
Primary care visits
Quartile 1 (Low)
Quartile 2
Quartile 3

Quartile 4 (High)

Model 2
95%CI

Model 3
Sig
ARR 95%CI
Biological Risk Factors

Sig

1.49
0.98
0.46

[ 1.32 , 1.69] ***
1.35
[ 1.18 , 1.53]
[ 0.83 , 1.16]
0.88
[ 0.74 , 1.05]
[ 0.40 , 0.53] ***
0.43
[ 0.37 , 0.50]
Individual Physical Make-up

***

1.25
1.05
1.08

[ 1.09 , 1.43]
[ 0.92 , 1.21]
[ 0.94 , 1.24]

0.73
1.10
0.52
1.78

[ 0.61 ,
[ 0.83 ,
[ 0.41 ,
[ 0.66 ,

1.40
1.46
1.02

[ 1.19 , 1.66]
[ 1.30 , 1.63]
[ 0.83 , 1.26]

1.02
0.92
0.94

[ 0.83 , 1.25]
[ 0.77 , 1.10]
[ 0.80 , 1.10]

0.79
0.84
0.84

[ 0.64 , 0.97]
[ 0.71 , 1.00]
[ 0.72 , 0.98]

1.02
1.01
1.49

[ 0.83 , 1.27]
[ 0.86 , 1.19]
[ 1.28 , 1.75]

0.87]
1.46]
0.66]
4.79]

**

1.27
1.08
1.08

***

0.74
1.06
***
0.56
2.12
Social support
***
***

1.32
1.37
1.02
Access to care

*
*

[ 0.62 ,
[ 0.80 ,
[ 0.44 ,
[ 0.80 ,

0.89]
1.40]
0.71]
5.60]

[ 1.11 , 1.56]
[ 1.22 , 1.54]
[ 0.82 , 1.26]

Model 4
95%CI

Sig

1.28
0.84
0.41

[ 1.12 , 1.46]
[ 0.70 , 1.00]
[ 0.34 , 0.49]

***

***

1.31
1.12
1.11

[ 1.13 , 1.52]
[ 0.97 , 1.29]
[ 0.96 , 1.28]

***

**

0.72
1.03
0.55
2.11

[ 0.59 ,
[ 0.77 ,
[ 0.43 ,
[ 0.80 ,

0.86]
1.37]
0.70]
5.58]

***

1.29
1.35
1.00

[ 1.09 , 1.53]
[ 1.20 , 1.52]
[ 0.81 , 1.23]

**
***

***

***

**
***

***

***

0.99
0.90
0.93

[ 0.81 , 1.22]
[ 0.75 , 1.08]
[ 0.79 , 1.09]

1.04
0.94
0.95

[ 0.83 , 1.30]
[ 0.78 , 1.14]
[ 0.80 , 1.12]

0.99
0.90
0.93

[ 0.81 , 1.22]
[ 0.75 , 1.08]
[ 0.79 , 1.09]

0.83
0.89
0.87

[ 0.67 , 1.03]
[ 0.74 , 1.07]
[ 0.75 , 1.02]

[ 0.83 , 1.27]
[ 0.85 , 1.18]
[ 1.07 , 1.50]

1.03
0.98
1.27

[ 0.83 , 1.27]
[ 0.83 , 1.15]
[ 1.08 , 1.50]

**

1.28

[ 1.03 , 1.60]

*

3.72

[ 3.26 , 4.24]

***

1.02
1.00
***
1.27
Health behaviors

Tobacco Use
Yes
No (Ref.)

[ 1.11 , 1.47]
[ 0.94 , 1.24]
[ 0.94 , 1.25]

ARR

1.22

**

[ 0.97 , 1.52]

Psychological factors
Anxiety-PTSD
Yes
No (Ref.)

3.66
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[ 3.21 , 4.17]
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Appendix 2.1
Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log Regression on
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and
Prostate Cancer SEER-Medicare Database, 2007-2012
ARR

Model 2
95%CI

Sig

ARR

Model 3
95%CI

Sig

ARR

Model 4
95%CI

Sig

Biological risk factors
Cardiovascular
Yes
No (Ref.)
Musculoskeletal disease
Yes
No (Ref.)
Respiratory
Yes
No (Ref.)
Stage at cancer diagnosis
Stage 0
Stage I (Ref.)
Stage II
Stage III
Stage IV

1.00

[ 0.87 , 1.15]

1.19

[ 1.07 , 1.34]

1.11

[ 0.96 , 1.27]

0.98

[ 0.82 , 1.18]

1.22
[ 1.06, 1.40]
1.41
[ 1.19 , 1.68]
1.63
[ 1.31, 2.03]
Treatment factors

Chemotherapy
Yes
No (Ref.)
Radiation therapy
Yes
No (Ref.)
Continued
Surgery
Yes
No (Ref.)

1.00

[ 0.87 , 1.15]

1.19

[ 1.07 , 1.33]

1.10

[ 0.96 , 1.27]

***

0.98

[ 0.82 , 1.18]

***

**
***
***

1.21
1.39
1.61

[ 1.06 , 1.40]
[ 1.17 , 1.68]
[ 1.30, 2.00]

**
***
***

1.01

[ 0.90 , 1.14]

0.83

[ 0.74 , 0.93]

0.97

[ 0.84 , 1.12]

1.11

[ 0.99 , 1.24]

0.93
0.94

[ 0.77 , 1.12]
[ 0.79 , 1.12]

0.96
1.00
0.98

[ 0.82 , 1.12]
[ 0.88 , 1.15]
[ 0.83 , 1.16]

1.03

[ 0.89 , 1.20]

**

Community Resources
Community mental health center
Yes
No (Ref.)
HPSA- Mental Health Care
Whole county
Part county
No shortage (Ref.)
Geographical Location
Region
Northeast
South
North-central
West (Ref.)
Metro status
Metro county
Non metro county (Ref.)
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Appendix 2.1
Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log Regression on
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and
Prostate Cancer SEER-Medicare Database, 2007-2012
ARR

Model 2
95%CI

Sig

Year at cancer diagnosis
2007
2008
2009
2010
2011 (Ref.)

ARR

Model 3
95%CI

Sig

ARR

0.98
1.14
1.05
1.06

Model 4
95%CI

[ 0.83 ,
[ 0.99 ,
[ 0.91 ,
[ 0.92 ,

Sig

1.15]
1.32]
1.22]
1.23]

Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate cancer who
were continuously enrolled in Medicare Part A and B during the observation period and who were alive during the observation
period. Asterisks represent significant differences in newly-diagnosed depression by cancer types, derived from complementary
log-log regression.
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05.
Model 1: Adjusted for cancer types. Model 2: Adjusted for cancer types and individual physical make-up; Model 3: Adjusted for
cancer types, access to care, health behaviors, and biological risk factors. Model 4: adjusted cancer types, access to care, health
behaviors, biological risk factors, treatment factors, community resources, geographical location, and year at cancer diagnosis.
Asterisks (*) represent significant differences based on complementary log log regressions with women cancer types as the
reference groups
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05.
AA: African American; ARR: Adjusted Risk Ratio; CMHC: Community Mental Health Center; HH: household; HS: High
school; HPSA: health professional shortage area; LT: less than; RR: Risk Ratio; Ref: Reference Group; SEER: Surveillance
Epidemiology and End Results; Sep/div/wid: Separated/Divorced/Widowed.
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Appendix 2.2 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare
Beneficiaries Diagnosed with Incident Breast, Colorectal and Prostate cancer


Cancer diagnosed identified using Siterwho 1- -10 codes
Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994

Diagnosed with cancer from April 2007 to Dec 2011
Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505


Diagnosed with cancer from April 2007 to Dec 2011

Primary cancer only in the patient’s lifetime (Seq1 in “00”)

Not diagnosed with cancer at autopsy or death certificate

Incident cases
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783


Elderly with cancer from April 2007 to Dec 2011

With primary cancer (Seq1 in “00”)

Not diagnosed with cancer at autopsy or death certificate

Incident cases, >=66, alive
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585





Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate ,
Incident cases, >=66, alive

Fee-for-service continuous enrollment and part D enrollment
3m before cancer dx
Breast N = 23,632, Colorectal N= 13,988, Prostate N= 24,726

Reason for exclusion:
 Not one primary cancer (Breast
n=39,257, Colorectal n=34,683,
Prostate n=34,738)
 Diagnosed at autopsy or death cert.
(Breast n=854, Colorectal n=1,061,
Prostate n=1,545)
 Not incident cases (Breast n=33,418,
Colorectal n=30,827, Prostate
Reasons for exclusion:
 <66 years old (Breast n=47,290,
Colorectal n=23,744, Prostate
n=56,295)
 Unknown stage of cancer (Breast
Colorectal n=6,614, Prostate
n=4,619, n=10,185)
 Death (Breast n=4,063, Colorectal

Reasons for exclusion:
 HMO enrollment (Breast n=23,647, Prostate
n=14,362, n=30,104)
 No Continuous enroll in Part A & B (Breast
n=4,840, Colorectal n=3,545, Prostate
n=10,677)
 No Continuous enroll in Part D (Breast
n=21,377, Colorectal n=13,676, Prostate
n=32,954)

Reasons for exclusion:
 Not depression free before cancer dx (Breast
n=3,925, Colorectal n=2,060, Prostate
n=2,252)

Final Analytical Cohort





Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate
Incident cases, >=66, alive, Fee-for-service continuous
enrollment and part D enrollment 3m before cancer dx

Depression free
Breast N = 19,578, Colorectal N= 11,841, Prostate N= 22,402

(N = 53,821)
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Chapter 3
Depression Treatment among Elderly Medicare Beneficiaries with Incident
Cancer and Newly-Diagnosed Depression
3.1 Abstract
Objective. Depression treatment can improve the health outcomes of elderly cancer survivors.
However, there is a paucity of studies on the extent to which newly-diagnosed depression is
treated among elderly cancer survivors. Therefore, the primary objective of this study is to
estimate the rates of treatment for newly-diagnosed depression and to identify the factors
affecting depression treatment among elderly individuals with incident cancer.
Methods. This study adopted a retrospective cohort study design with data from the linked
Surveillance, Epidemiology and End Results (SEER) and Medicare database. Elderly individuals
(> 66 years) with incident breast, colorectal or prostate cancer and newly diagnosed depression
(N= 1,673) were followed for six months after depression diagnosis date to identify depression
treatment. Depression treatment was categorized into four mutually exclusive categories: 1)
treatment with only antidepressants; 2) treatment with only psychotherapy; 3) combined
treatment with both antidepressants and psychotherapy; and 4) no depression treatment. Chisquare tests and multinomial logistic regressions were used to analyze the factors (predisposing,
enabling and need factors as well as the external environment) associated with depression
treatment.
Results. In our study population, 45.7% received only antidepressants, 8.8% received only
psychotherapy, 18.4% received combined therapy and 27.1% received no treatment for
depression. This study found that cancer survivors who received cancer treatment after
depression diagnosis were less likely to receive psychotherapy only (Adjusted Odds Ratio
(AOR) = 0.40 [95%CI, 0.22-0.72]), or combined therapy (AOR = 0.51 [95%CI, 0.34-0.79]), as
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compared to those who received cancer treatment before depression diagnosis. This study also
found that residents living in counties with a higher percentage of psychologists were more likely
to receive psychotherapy only (Adjusted Odds Ratio (AOR) = 2.17 [95%CI, 1.20-3.90]), or
combined therapy (AOR = 1.55 [95%CI, 1.03-2.33]). Other factors associated with depression
treatment were: race, the number of primary care physician visits, the presence of other chronic
conditions, and anxiety.
Conclusion. The study findings indicate that two-third of cancer survivors received some
depression treatment in the first six months after depression diagnosis. The majority of cancer
survivors received antidepressants only to treat newly-diagnosed depression. Certain
predisposing, enabling and need factors as well as external environmental factors were
associated with depression treatment.
Implications. Despite the clinical guidelines’ recommendations for treating depression among
cancer survivors, one-fourth of cancer survivors do not receive any depression treatment. Future
research needs to investigate whether these individuals receive alternative therapies for newlydiagnosed depression.
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3.2 Introduction
Depression is a treatable and highly prevalent mental health condition among cancer
survivors (1,2). Relief from clinical depression can be achieved with either pharmacotherapy or
psychotherapy or a combination of pharmacotherapy and psychotherapy (3). Pharmacotherapy
typically consists of antidepressants such as selective serotonin reuptake inhibitors (SSRIs),
selective norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),
monoamine oxidase inhibitors (MAOIs) and others (mirtazapine, bupropion) (3). Different forms
of psychotherapy are used to treat depression such as cognitive-behavioral therapy and problemsolving therapy (3).
The efficacy of antidepressants for treating depression among older adults (age > 65
years) in the general population (4,5) and cancer survivors (6-12) has been evaluated by many
randomized clinical trials (RCTs). These trials have not yet established the efficacy of
antidepressants in treating depression among older adults. For example, a meta-analysis of six
double-blind RCTs involving patients aged 65 and older found no statistically significant
differences between the treatment with antidepressants and the placebo groups (Relative Risk =
1.13; 95% CI: 0.93–1.37, p = 0.265) (4,5). Among cancer survivors, there is mixed evidence
from seven RCTs on the efficacy of antidepressants in treating cancer patients with depression.
In five RCTs, cancer patients who used antidepressants were more likely to achieve a therapeutic
response as compared to the placebo (6-10). However, in two RCTs antidepressants were not
found to be efficacious (11,12). The efficacy of psychotherapy alone in treating depression has
been established efficacy for elderly individuals in the general population (13) and among adults
with cancer (14-18). In addition, the combination of antidepressants and psychotherapy has an
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established efficacy in reducing depressive symptoms, in some RCTs, among the elderly in the
general population (19,20) but not among adults with cancer (21).
As various depression treatment modalities have been found to be efficacious among
older adults, clinical practice guidelines have recommended depression treatment for cancer
patients (22-24). These guidelines do not recommend antidepressants over psychotherapy alone
or in combination with antidepressants, nor do they recommend one antidepressant over another.
Although depression treatment is recommended to reduce the depressive symptoms for cancer
survivors, it is not known how depression is treated in the real-world clinical practice settings
among elderly with cancer. Research on treatment of newly-diagnosed depression among cancer
survivors has not received much attention. In the United States, only two cross-sectional studies
examined depression treatment among cancer survivors seeking care in real-world clinicalpractice settings (25,26). Of these two studies, one study focused on elderly (age > 65 years)
Medicare beneficiaries with cancer using data between 2000 and 2005 (25) and another study
used MEPS from multiple years 2006-2008 among adults with both cancer and depression (26).
Findings from these studies revealed that an estimated 76% and 84% of elderly cancer survivors
received any depression treatment. These studies were among cancer survivors with prevalent
depression and any type of cancer. These studies did not include cancer-related clinical factors
such as stage at cancer diagnosis and cancer treatment, which might affect depression treatment.
Furthermore, these studies used self-reported data on either antidepressant use or depression
diagnosis.
There are no studies that examined the treatment of depression among cancer survivors
with newly-diagnosed depression. In addition, no studies distinguish depression treatment among
specific types of cancer such as breast, colorectal, or prostate cancer. Therefore, the primary
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objective of the current study was to fill the knowledge gap in estimating depression treatment
and the factors associated with depression treatment among breast, colorectal or prostate cancer
survivors with newly-diagnosed depression. This study used a retrospective cohort design with
data from clinical care encounters and prescription drug claims to analyze depression treatment
among cancer survivors with newly-diagnosed depression. These cancers were selected due to
their high prevalence; they are projected to be the most common types of cancer by 2024, with
breast cancer among women expected to be 41%, prostate cancer among men to be 45%, and
colorectal cancer among men and women to be 8%.
3.3 Conceptual framework
The expanded behavioral model on healthcare utilization, the Andersen Behavioral
Model, was used to guide the selection of factors that may affect depression treatment (27).
According to this model, depression treatment (i.e. health services utilization) is a function of: 1)
an individual’s predisposition to utilize the services – predisposing factors; 2) factors which
enable individuals to use healthcare services – enabling factors; 3) an individual’s level of need –
need factors; 4) personal health practices, and 5) the external environment.
3.4 Methods
3.4.1 Study Design
This study utilized retrospective cohort study design with baseline and follow-up periods.
The first observed date of depression diagnosis after cancer diagnosis was considered as an index
date. The baseline period was defined as 12 months before this index date and the follow-up
period was defined as six months after this index date.
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3.4.2 Data Sources
The current study linked data from several sources including the SEER-Medicare linked
database and the AHRF files. The detailed description of the data sources are provided in
Chapter 1.
3.4.3 Study population
Identification of Cancer Survivors
The study population composed of elderly cancer survivors (age > 66 years) who were
diagnosed with primary only incident breast, colorectal or prostate cancer and newly-diagnosed
depression between 2007 and 2011. Cancer types (breast, colorectal or prostate cancer) was
identified using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O3) histology codes and the primary site variable.
Cancer Survivors with newly-diagnosed depression
This study identified cancer survivors with newly-diagnosed depression based on the
National Committee on Quality Assurance (NCQA) criteria (30). To accomplish this, a
depression-free cancer cohort with incident cancer diagnosis between April 2007 and December
2011 was first established. To identify newly-diagnosed depression after cancer diagnosis, only
those who were diagnosed with depression after cancer diagnosis and did not have any
antidepressant use 90 days prior to depression diagnosis were included. This study used a
validated algorithm developed by the Centers for Medicare and Medicaid Services (CMS)
Chronic Conditions Data Warehouse (CCW) to identify depression (31) using the International
Classifications of Diseases – 9th edition, Clinical Modification (ICD-9-CM) Codes ( 296.2,
296.3, 298.0, 300.4, 309.1, and 311.0). These codes are widely used in the literature to identify
depression diagnoses among Medicare beneficiaries (1,25,32).
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Inclusion/exclusion criteria
This study required that all individuals have continuous enrollment in Medicare part A, B
and no enrollment in managed care plans during the baseline and follow-up periods. This study
also required that individuals have continuous enrollment in Medicare part D six months after
depression diagnosis to identify depression treatment in the follow-up period. This study
excluded individuals with unknown cancer stage at diagnosis, those diagnosed through autopsy
or death certificate, or those who died during the follow-up period. Appendix 1.1 demonstrates
the analytical population selection process. The final study population consisted of 1,673 elderly
Medicare beneficiaries with newly-diagnosed depression and incident breast, colorectal or
prostate cancer.
3.4.4 Dependent Variable: Depression Treatment
This study identified depression treatment during the first six months after depression
diagnosis. Antidepressant use was derived from Medicare Part D claims using the National Drug
Codes (NDC) and generic names. Antidepressants included SSRIs, SNRIs, TCAs, MAOIs and
others (mirtazapine, bupropion). Any cancer survivors with at least one prescription for
antidepressants was considered as using antidepressants. Psychotherapy visits were derived from
Medicare outpatient claims using the Current Procedural Terminology (CPT) codes. Any cancer
survivor with at least one psychotherapy visit was considered as receiving psychotherapy.
Based on antidepressant prescriptions and psychotherapy visits, depression treatment was
categorized into four mutually exclusive categories: (1) treatment with antidepressants only:
individuals received, at least, one prescription of antidepressants and no psychotherapy visit; (2)
treatment with psychotherapy only: individuals had, at least, one psychotherapy office visit and
no prescription for antidepressants; (3) both antidepressants and psychotherapy: individuals
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received, at least, one prescription for antidepressants with at least one psychotherapy visit; (4)
no treatment: individuals received no antidepressants and no psychotherapy.
3.4.5 Independent Variables
Predisposing factors included age in years at cancer diagnosis (66-69, 70-74, 75-79,
>=80) and race (White, African American, and others). Enabling factors consisted of marital
status (married, divorced/separated/widowed, and never married); number of visits to primary
care physicians (PCP) by patients (measured in quartiles); cancer types (women with breast
cancer, women with colorectal cancer, men with colorectal cancer, men with prostate cancer);
stage at cancer diagnosis (categorized using American Joint Committee on Cancer (AJCC)
grouped staging (stage 0/I, stage II, and stage III, stage IV) and cancer treatment with
chemotherapy, radiation therapy, radiation therapy or surgery. As cancer is often considered a
dominant condition and cancer treatment after depression diagnosis may compete with
depression care, cancer treatment was cateorized into three groups:1) cancer treatment before
depression diagnosis; 2) cancer treatment at or after depression diagnosis, and 3) no cancer
treatment. Need factors composed of chronic conditions, which were selected, based on the
Multiple Chronic Conditions working group framework (33). The following chronic conditions
were used: Alzheimer's disease and related disorders (ADRD); anxiety; cardiovascular (diabetes,
heart disease (cardiac arrythmia, coronary heart disease, congestive heart faliure),
hyperlipidemia, hypertension, and stroke); musculoskeletal (arthritis, and osteoporosis) and
respiratory conditions (asthma and chronic obstructive pulmonary disorder). This study
identified these conditions based on a validated algorithm developed by the CMS Chronic
Conditions Data Warehouse (31); according to this algorithm, individuals had, at least, one
inpatient visit or two outpatient visits during the baseline period. External Environment factors
included the county-level percentage of psychologists and SEER region (Northeast, South,
62

North-central, and West). This study also controlled for year of cancer diagnosis by grouping the
years into two groups: 1) 2007-2009, the period when FDA issued a black box warning due to
the risk of suicides with antidepressants use (34,35) and 2) 2010-2011, the period when
published articles reported the association between antidepressants and the risk of new-onset
diabetes (36). This study did not use metro status because it was highly correlated with the
county-level percentage of psychologists.

3.5 Statistical Analysis
This study used Chi-square tests and multinomial logistic regressions to examine the
unadjusted differences in subgroups by depression treatment categories. This study used
multivariable multinomial logistic regressions to examine the adjusted association between the
independent variables and depression treatment categories. In these regressions, predisposing,
enabling, need, and external environment factors were included. In all these models, the
reference group for the dependent variable was “no depression treatment”. All statistical
analyses were carried out in SAS 9.4 (SAS Institute Inc., Cary, NC).
3.6 Results
3.6.1 Characteristics of the study population
The study population consisted of 1,673 elderly fee-for-service Medicare beneficiaries
with incident breast, colorectal or prostate cancer who had newly-diagnosed depression after
cancer diagnosis. In this study population, 44.9% were women with breast cancer; 22.8% were
women with colorectal cancer; 10.1% were men with colorectal cancer, and 22.2% were men
with prostate cancer. This study found that 35.0% were diagnosed with early stage cancers (stage
0/I) and 7.1% diagnosed at an advanced stage (stage IV); 68.0% received cancer treatment before
depression diagnosis, 21.4% received cancer treatment on or after depression diagnosis, and
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10.6% did not receive cancer treatment. The description of the study population is presented in
Table 1.
Tables 2 and 3 display the unadjusted associations between predisposing, enabling and
need factors, and external environment and depression treatment categories. Among elderly
cancer survivors with newly-diagnosed depression, This study found that 27.1% did not receive
any depression treatment; 45.7% received antidepressants only; 8.8% received psychotherapy
only, and 18.4% received both antidepressants and psychotherapy. There was a significant
difference in antidepressant use only by predisposing characteristics (race). For example, a
significantly lower percentage of African American (odds ratio (OR) = 0.49, 95% Confidence
interval (CI) = 0.31, 0.77) used antidepressants only as compared to whites (28.3% versus
47.9%); similarly, a lower percentage of other racial minorities (odds ratio (OR) = 0.54, 95%
(CI) = 0.36, 0.82) used antidepressants only as compared to whites (41.5 versus 47.9%).
With regard to the use of psychotherapy only, This study found significant differences in
psychotherapy use by enabling factors (marital status, PCP visits, cancer treatment), need factors
(ADRD, anxiety, respiratory conditions), and external environmental characteristics (countylevel percentage of psychologists and region of residence). For example, a significantly lower
percentage of individuals who received cancer treatment after depression diagnosis (OR = 0.40,
95% (CI) = 0.23, 0.70) used psychotherapy as compared to those who received cancer treatment
before depression diagnosis (4.7% versus 9.3%). Individuals with ADRD had a higher use of
psychotherapy (OR = 3.27, 95% (CI) = 1.93, 5.56) as compared to those without ADRD (15.1%
versus 7.9%).
This study found significant group differences in the use of combination of
antidepressant and psychotherapy by predisposing factor (race), enabling factors (never married,
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cancer treatment, and the number of PCP visits), need factors (ADRD, cardiovascular), and
external environment (county-level number of psychologists and region of residence). For
example, other racial minorities were less likely to receive combination of antidepressant and
psychotherapy (OR = 0.41, 95% (CI) = 0.23, 0.74) as compared to whites (11.9% versus 18.1%).
Individuals with a higher number of PCP visits had higher use of combined
antidepressant/psychotherapy (OR = 1.03, 95% (CI) = 1.01, 1.05).
Table 4 presents the adjusted odds ratios (AOR) and 95% CIs from multinomial logistic
regressions of depression treatment categories. In these regressions, “no depression treatment”
was used as the reference group of the dependent variable. The results were generally consistent
with the unadjusted analyses. This study found significant associations between a predisposing
factor (race) and only antidepressants use. African Americans were less likely to receive
antidepressants only as compared to White (AOR = 0.44, 95% (CI) = 0.27, 0.70). This study also
found a significant association between psychotherapy use and enabling factors (marital status,
PCP visits, and cancer treatment), need factors (ADRD, anxiety, cardiovascular, and respiratory
conditions), and external environment (county-level percentage of psychologists, region of
residence). For example, Individuals with higher number of PCP visits were more likely to use
psychotherapy (AOR = 1.02, 95% (CI) = 1.00, 1.04). Individuals who received cancer treatment
after depression diagnosis were less likely to use psychotherapy as compared to those who
received cancer treatment before depression diagnosis (AOR = 0.40, 95% (CI) = 0.22, 0.72).
With regard to combined antidepressants/psychotherapy, this study found a significant
association between combined antidepressants/psychotherapy use and predisposing factor (race),
enabling factors (PCP visits, cancer treatment), need factors (ADRD) and external environment
(county-level percentage of psychologists, region of residence). For example, residents living in
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counties with a higher percentage of psychologists were more likely to receive combined
antidepressants/psychotherapy (AOR = 1.05 [95%CI, 1.00-1.09]). AOR and 95% CI for other
independent variables are presented in Table 4.
Of particular interest was the cancer types (Appendix 1.2). This study found that there
were not significant differences in depression treatment categories between women with
colorectal cancer as compared to women with women with breast cancer (AOR = 0.93 [95%CI,
0.67-1.29]); and between men with colorectal cancer as compared to men with prostate cancer
(AOR = 0.79 [95%CI, 0.48-1.30]).
3.7 Discussion
In this study, the rates of depression treatment and the factors associated with depression
treatment for newly-diagnosed depression were estimated among elderly cancer survivors with
incident breast, colorectal or prostate cancer. In our study population, one in four cancer
survivors did not receive either antidepressants or psychotherapy for depression. This finding is
consistent with the one published study depression treatment rate among elderly Medicare
beneficiaries with cancer (25). Less than 50% of cancer survivors were treated with
antidepressants only and 27.2% used psychotherapy with or without antidepressants. The
percentage of antidepressant use is somewhat lower, and the psychotherapy use is higher than the
estimated rates reported in one published study of Medicare beneficiaries with cancer (25). The
differences between our study and the published study could be due to differences in the study
designs (retrospective cross-sectional versus retrospective cohort), measurement of
antidepressants (self-report versus prescription claims), and identification of depression
(prevalent versus newly-diagnosed depression).

66

This study also found that only one predisposing factor (race) was associated with the use
of “antidepressants only.” African Americans and other racial minorities were less likely to use
antidepressants only as compared to whites. Such racial disparities have been documented
among elderly Medicare beneficiaries with cancer (25) as well as in the elderly population. Some
studies have attributed the racial disparities in antidepressant use to cultural factors. For
example, it has been documented that African Americans and other racial minorities were less
likely to accept antidepressants medications as compared to whites (37). A meta-analysis of
cultural mistrust and mental health services for African Americans suggested a significant
association between cultural mistrust with mental health services use (38).
Psychotherapy only or combined use of antidepressants and psychotherapy were
associated with many factors (enabling, need, and external environment factors). Regarding
enabling factors, cancer survivors with a higher number of PCP visits were more likely to receive
psychotherapy and a combination of antidepressants and psychotherapy as compared to those
with a lower number of PCP visits. This finding suggests that PCP visits may play an important
role in referring cancer survivors to mental healthcare providers for psychotherapy treatment. A
national survey of physicians conducted by the Cancer Care Outcomes Research and
Surveillance Consortium has shown that PCPs are more involved in detection and treatment of
depression in cancer survivors as compared to oncologists (50% vs. 18%) (39).
As expected, This study found that those who had initiated cancer treatment after
depression diagnosis were less likely to receive psychotherapy as compared to those who had
initiated cancer treatment before depression diagnosis. As psychotherapy sessions involve faceto-face visits to the mental health providers, cancer survivors may not be able to receive
psychotherapy while cancer treatment is ongoing. These findings provide some evidence to
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support the theory of competing demands for care, which suggests that cancer is a dominant
condition and may “eclipse the management of other health conditions.” (40).
Further, This study found that many co-existing chronic conditions were associated with
depression treatment. Cancer survivors with respiratory conditions were more likely to receive
psychotherapy treatment as compared to those without respiratory conditions. This is not
surprising because psychotherapy is a standard part of the rehabilitation therapy regimen, which
is used to treat respiratory conditions such as asthma and COPD (41,42). This study also found
that individuals with ADRD were more likely to receive psychotherapy and a combination of
antidepressants and psychotherapy as compared to those without ADRD. Cognitive therapy and
other psychotherapies are some treatment modalities that are used to improve dementia
symptoms (43). Further, the presence of cardiovascular conditions and anxiety were negatively
associated with depression treatment. For example, those with cardiovascular conditions were
less likely to use psychotherapy only as compared to those without cardiovascular conditions.
While the reasons for this are not known, the lack of robust evidence of depression treatment on
cardiac outcomes from RCTs (44,45) may discourage physicians from recommending treatment
for depression. For example, one of the RCTs, which used psychotherapy as the main modality
of treatment for individuals with depression and heart disease, found no significant differences in
cardiac outcomes (44). As none of the trials have shown improvement in cardiac outcomes, there
have been calls for more trials to establish the efficacy of depression treatment on chronic care
outcomes (46). This study also found that those with pre-existing anxiety were less likely to
receive treatment as compared to those without anxiety. However, existing studies have shown
that comorbid anxiety is associated with higher treatment rates among elderly Medicare
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beneficiaries. Thus, the difference in findings could be attributed to the measurement period in
which anxiety was identified.
External environmental characteristics were also associated with depression treatment
categories. This study found that the supply of mental health services was associated with
psychotherapy use. For example, This study observed that a higher percentage of psychologists
in a county was significantly associated with psychotherapy use and with a combination of
antidepressants and psychotherapy use. This is also consistent with the published literature,
which found that the availability of psychotherapy providers influences psychotherapy use (47).
This study has filled a knowledge gap by estimating the rates and identifing the factors
associated with depression treatment categories among those with newly-diagnosed depression
and incident breast, colorectal or prostate cancer. Our study findings indicate that racial
disparities in depression treatment persist, competing demands may impede depression care and
that the availability of psychologists may influence receipt of psychotherapy among cancer
survivors. The current study made unique contributions to the nascent literature on depression
care among cancer survivors. It has to be noted that once diagnosed with depression, neither
type of cancer nor stage of cancer were associated with depression treatment, suggesting that
detecting depression and diagnosing depression is critical to depression management among
cancer survivors.
Strengths and limitations
This study’s findings need to be interpreted in the context of its advantages and
limitations. One advantage is that this study used linked cancer registry and claims data in which
a large cohort of cancer survivors were followed six months to identify their depression
treatment. Another advantage is that this study used different data sources and controlled for a
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comprehensive list of factors including the county-level percentage of psychologists and clinical
factors such as cancer stage and cancer treatment that may affect the rates of depression
treatment. A third advantage is that this study used Medicare part D to identify antidepressant
treatment rates. This study also has some limitations. As the study population was restricted to
fee-for-service Medicare beneficiaries, those residing in SEER regions and those who had
Medicare part D coverage the study findings are not generalizable to all Medicare beneficiaries.
Although other effective treatments for depression exist such as electroconvulsive therapy, this
study focused on antidepressants and psychotherapy because they are the most commonly used
depression treatment. While this study captured many variables that may be associated with the
rates of depression treatment, some important variables such patient preferences were lacking. In
addition, the reasons for no depression treatment was not explored in this study. This study can
speculate that some elderly with cancer may not receive depression treatment because of
competing demands of healthcare management and the prioritization of treatment of cancer.
Also, providers may not prescribe antidepressants for treating depression due to the lack of
robust evidence base.

3.8 Conclusion
Even with a successful diagnosis of depression in the oncology setting, a treatment gap
exists. One-fourth of cancer survivors with newly-diagnosed depression did not receive any
depression treatment. Therefore, greater effort is needed to ensure that cancer survivors are
receiving depression treatment, especially for cancer survivors who initiated cancer treatment
after depression diagnosis, as competing demands can impede depression care. Depression care
can be imrpved by increasing the contact of cancer survivors with primary care providers and
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increase the supply of mental health services. Also, reducing racial disparities is important to
improve depression care.
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Table 3.1
Description of the Study Population Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed
Depression,
SEER-Medicare Database, 2007-2012
N

%

1,673

100.0

66-69

434

25.9

70-74

430

25.7

75-79

342

20.4

>=80

467

27.9

1,393

83.3

AA

145

8.7

Others

135

8.1

Married

649

38.8

Never married

177

10.6

Sep/div/wid/Unkn

847

50.6

Total
Predisposing factors
Age in years

Race
White

Enabling factors
Marital Status

10.18 (10.08)

Primary care visits (mean (SD))
Cancer type
Breast

752

44.9

Women colorectal

381

22.8

Men colorectal

169

10.1

Prostate

371

22.2

Stage 0-I

586

35.0

Stage II

720

43.0

Stage III

249

14.9

Stage IV

118

7.1

1,137

68.0

After dep. Dx

358

21.4

No treatment

178

10.6

Cancer Stage

Cancer treatment
Before dep. Dx

Continued,
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Table 3.1
Description of the Study Population Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed
Depression,
SEER-Medicare Database, 2007-2012
N

%

1,469

90.8

148

9.2

Need factors
Cardiovascular
Yes
No
Musculoskeletal
Yes
No

543

33.6

1,074

66.4

379

23.4

1,238

76.6

219

13.1

1,454

86.9

437

26.1

1,236

73.9

Respiratory
Yes
No
Dementia
Yes
No
Anxiety
Yes
No
External Environment
2.37 (4.21)

% Psychologists (mean (SD))
Region
Northeast

323

19.3

south

457

27.3

North-central

212

12.7

West

681

40.7

954

57.0

719

43.0

Cancer diagnosis year
2007-2009
2010-2012

Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period and who were alive during the observation period.
AA: African American; ADRD: Alzheimer's disease and related disorders; dep: Depression; dx: diagnosis; SEER:
Surveillance Epidemiology and End Results; Sep/div/wid/unkn: Separated/Divorced/Widowed/unknown; SD:
Standard deviation.
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Table 3.2
Description of the Study Population by Depression Treatment Categories
Elderly Fee-for-service Medicare beneficiaries with Breast, Colorectal or Prostate Cancer and Newlydiagnosed Depression
SEER-Medicare Database, 2007-2012
Antidepressants
Only
All

Psychotherapy
Only

Combined
ADs/Psych

No
Treatment

N

%

N

%

N

%

N

%

764

45.7

148

8.8

308

18.4

453

27.1

chisq

sig

Predisposing factors
Age in years
66-69
70-74

8.6
208
199

47.9
46.3

39
36

9.0
8.4

82
71

18.9
16.5

105
124

24.2
28.8

75-79

158

46.2

23

6.7

63

18.4

98

28.7

>=80

199

42.6

50

10.7

92

19.7

126

27.0

Race
White
AA

667
41

47.9
28.3

115
23

8.3
15.9

252
40

18.1
27.6

359
41

25.8
28.3

Others

56

41.5

13

7.4

16

11.9

53

39.3

38.8

***

28.7

***

Enabling factors
Marital Status
Married
Never married
Sep/div/wid/Unkn
Primary care visits
(mean (SD))
Cancer type
Breast
Women
colorectal
Men colorectal

305

47.0

41

6.3

112

17.3

191

29.4

64
395

36.2
46.6

26
81

14.7
9.6

49
147

27.7
17.4

38
224

21.5
26.4

9.23 (9.06)

13.07 (13.83)

12.27 ( 11.75)

9.41(8.58)

***
12.4

369

49.1

58

7.7

130

17.3

195

25.9

165
67

43.3
39.6

40
22

10.5
13.0

71
31

18.6
18.3

105
49

27.6
29.0

Prostate

163

43.9

28

7.5

76

20.5

104

28.0

Cancer Stage
Stage 0/I

276

47.1

50

8.5

106

18.1

154

26.3

Stage II
Stage III

321
115

44.6
46.2

59
27

8.2
10.8

137
47

19.0
18.9

203
60

28.2
24.1

Stage IV

52

44.1

12

10.2

18

15.3

36

30.5

4.9

36.4

Cancer treatment
Before dep dx

507

44.6

106

9.3

227

20.0

297

26.1

After dep dx
No treatment

194
63

54.2
35.4

17
25

4.7
14.0

41
40

11.5
22.5

106
50

29.6
28.1

77

***

Table 3.2
Description of the Study Population by Depression Treatment Categories
Elderly Fee-for-service Medicare beneficiaries with Breast, Colorectal or Prostate Cancer and Newlydiagnosed Depression
SEER-Medicare Database, 2007-2012
Antidepressants
Only
N

Psychotherapy
Only

%

N

Combined
ADs/Psych

%

N

%

No
Treatment
N

%

chisq

sig

Continued,
Need factors
Cardiovascular
Yes
No
Musculoskeletal
Yes
No
Respiratory
Yes
No

10.6
691

47.0

127

8.6

292

19.9

359

24.4

73

49.3

21

14.2

16

10.8

38

25.7

243

44.8

48

8.8

121

22.3

131

24.1

521

48.5

100

9.3

187

17.4

266

24.8

174
590

45.9
47.7

47
101

12.4
8.2

79
229

20.8
18.5

79
318

20.8
25.7

*

5.7

9.5

ADRD
Yes

83

37.9

33

15.1

71

32.4

32

14.6

No

681

46.8

115

7.9

237

16.3

421

29.0

Anxiety
Yes

205

46.9

25

5.7

99

22.7

108

24.7

No

559

45.2

123

10.0

209

16.9

345

27.9

*

55.7

***

13.7

**

External Environment
% Psychologists
(mean (SD))
Region
Northeast
south
North-central
West
Cancer diagnosis year
2007-2009
2010-2012

2.04 (3.92)

3.08 (4.85)

2.81 (4.56)

2.49 (4.23)

***
59.3

121
243

37.5
53.2

43
24

13.3
5.3

89
60

27.6
13.1

70
130

21.7
28.4

92
308

43.4
45.2

23
58

10.8
8.5

49
110

23.1
16.2

48
205

22.6
30.1

***

19.4
104
178

39.8
48.1

30
36

11.5
9.7

45
61

17.2
16.5

82
95

31.4
25.7

Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study
population characteristics by depression treatment categories, derived from chi-square statistics.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
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AA: African American; ADs: Antidepressants; ADRD: Alzheimer's disease and related disorders; dep: Depression;
dx: diagnosis; SEER: Surveillance Epidemiology and End Results; Sep/div/wid/unkn:
Separated/Divorced/Widowed/unknown; SD: Standard deviation; Psych: psychotherapy.
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Table 3.3
Unadjusted Odds Ratios and 95% Confidence Intervals of Depression Treatment Categories
from Multinomial Logistic Regression on Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression
SEER-Medicare database, 2007-2012
Reference Group = No Depression Treatment
Antidepressants Only
Psychotherapy only
Combined ADs/Psych
OR
95%CI Sig
OR
95%CI
Sig
OR
95%CI Sig
Predisposing factors
Age in years
66-69
1.25 [ 0.89 , 1.75]
0.93 [ 0.56 , 1.54]
1.07 [ 0.71 , 1.60]
70-74
1.03 [ 0.74 , 1.43]
0.74 [ 0.45 , 1.23]
0.79 [ 0.53 , 1.19]
75-79
0.99 [ 0.70 , 1.41]
0.58 [ 0.33 , 1.01]
0.86 [ 0.56 , 1.31]
>=80 (Ref.)
Race
White (Ref.)
AA
0.49 [ 0.31 , 0.77] **
1.59 [ 0.91 , 2.78]
1.26 [ 0.79 , 2.02]
Others
0.54 [ 0.36 , 0.82] **
0.56 [ 0.27 , 1.15]
0.41 [ 0.23 , 0.74] **
Enabling factors
Marital Status
Married (Ref.)
Never married
1.03 [ 0.65 , 1.63]
3.11 [ 1.69 , 5.76] ***
2.15 [ 1.31 , 3.54] **
Sep/div/wid/Unkn
1.10 [ 0.86 , 1.42]
1.68 [ 1.10 , 2.58] *
1.12 [ 0.81 , 1.54]
Primary care visits
Cancer type
Breast (Ref.)
Women colorectal
Men colorectal
Prostate
Cancer Stage
Stage 0/I (Ref.)
Stage II
Stage III
Stage IV
Cancer treatment
Before Dep Dx. (Ref.)
After Dep Dx.
No Treatment
Cardiovascular
Yes
No (Ref.)

1.00

[ 0.99 , 1.02]

1.04

[ 1.02 , 1.05]

0.84
0.79
0.87

[ 0.62 , 1.15]
[ 0.52 , 1.22]
[ 0.63 , 1.19]

1.30
1.66
0.95

0.89
1.03
0.74

[ 0.68 , 1.17]
[ 0.70 , 1.52]
[ 0.46 , 1.20]

0.90
1.34
0.95

0.95
0.77

[ 0.72 , 1.26]
[ 0.51 , 1.17]

1.03

[ 1.01 , 1.05]

[ 0.81 , 2.09]
[ 0.91 , 3.02]
[ 0.57 , 1.59]

1.03
1.04
1.15

[ 0.70 , 1.51]
[ 0.62 , 1.76]
[ 0.79 , 1.68]

[ 0.58 , 1.40]
[ 0.76 , 2.36]
[ 0.45 , 1.97]

0.99
1.10
0.67

[ 0.71 , 1.39]
[ 0.69 , 1.75]
[ 0.36 , 1.25]

0.45
1.09

[ 0.30 , 0.67]
[ 0.68 , 1.75]

***

1.00

[ 0.66 , 1.51]

1.93

[ 1.06 , 3.53]

*

0.40 [ 0.23 , 0.70]
1.46 [ 0.85 , 2.52]
Need factors
0.64

Continued,
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[ 0.36 , 1.13]

***

**

***

Table 3.3
Unadjusted Odds Ratios and 95% Confidence Intervals of Depression Treatment Categories
from Multinomial Logistic Regression on Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression
SEER-Medicare database, 2007-2012
Reference Group = No Depression Treatment
Antidepressants Only
Psychotherapy only
Combined ADs/Psych
OR
95%CI Sig
OR
95%CI
Sig
OR
95%CI Sig
Musculoskeletal
Yes
0.95 [ 0.73 , 1.23]
0.97 [ 0.65 , 1.46]
1.31 [ 0.96 , 1.79]
No (Ref.)
Respiratory
Yes
1.19 [ 0.88 , 1.60]
1.87 [ 1.22 , 2.86] **
1.39 [ 0.97 , 1.98]
No (Ref.)
ADRD
Yes
1.39 [ 0.91 , 2.13]
3.27 [ 1.93 , 5.56] ***
3.42 [ 2.18 , 5.35] ***
No (Ref.)
Anxiety
Yes
0.98 [ 0.75 , 1.29]
0.54 [ 0.34 , 0.88] *
1.27 [ 0.92 , 1.76]
No (Ref.)
External Environment
% Psychologists
Region
Northeast
south
North-central
West (Ref.)
Cancer diagnosis
2007 (Ref.)
2008

0.99

[ 0.96 , 1.02]

1.05

[ 1.00 , 1.11]

*

1.05

[ 1.00 , 1.09]

*

1.08
1.17
1.38

[ 0.76 , 1.54]
[ 0.88 , 1.55]
[ 0.91 , 2.11]

2.04
0.61
1.84

[ 1.25 , 3.32]
[ 0.36 , 1.04]
[ 1.01 , 3.34]

**

2.23
0.81
2.06

[ 1.49 , 3.32]
[ 0.55 , 1.19]
[ 1.27 , 3.35]

***

0.84

[ 0.66 , 1.07]

0.82

[ 0.56 , 1.20]

0.99

[ 0.73 , 1.33]

*

Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study
population characteristics by depression treatment categories, derived from multinomial logistic regression.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
AA: African American; ADRD: Alzheimer's disease and related disorders; CI: Confidence interval; dep:
Depression; dx: diagnosis; OR: Odds ratio; SEER: Surveillance Epidemiology and End Results; Sep/div/wid/unkn:
Separated/Divorced/Widowed/unknown; SD: Standard deviation; Ref: Reference group; Psych: psychotherapy.
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Table 3.4
Adjusted Odds Ratios and 95% Confidence Intervals of Depression Treatment Categories
from Multinomial Logistic Regression on Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression
SEER-Medicare database, 2007-2012
Reference Group = No Depression Treatment
Antidepressants Only
AOR

95%CI

Psychotherapy only
Sig

AOR

95%CI

Combined AD/Psych
Sig

AOR

95%CI

Sig

Predisposing factors
Age in years
66-69
70-74
75-79
>=80 (Ref.)
Race
White (Ref.)
African Americans
Other races

1.39
1.14
1.01

[ 0.97 , 2.01]
[ 0.80 , 1.62]
[ 0.71 , 1.45]

0.44
0.59

[ 0.27 , 0.70]
[ 0.38 , 0.92]

***
*

1.41
1.15
0.75

[ 0.80 , 2.47]
[ 0.66 , 2.00]
[ 0.42 , 1.37]

1.52
1.07
0.96

[ 0.96 , 2.39]
[ 0.68 , 1.68]
[ 0.61 , 1.51]

1.19
0.49

[ 0.64 , 2.21]
[ 0.22 , 1.06]

1.02
0.38

[ 0.61 , 1.71]
[ 0.20 , 0.71]

**

Enabling factors
Marital Status
Married (Ref.)
Never married
Sep/div/wid/Unkn

1.14
1.15

[ 0.71 , 1.83]
[ 0.87 , 1.51]

2.33
1.57

[ 1.21 , 4.48]
[ 0.98 , 2.50]

*

1.68
1.02

[ 0.98 , 2.86]
[ 0.71 , 1.45]

PCP visits

1.00

[ 0.99 , 1.02]

1.02

[ 1.00 , 1.04]

*

1.02

[ 1.00 , 1.04]

Cancer types
Women Breast (Ref.)
Women Colorectal
Men Colorectal
Cancer
Men Prostate Cancer

0.93

[ 0.67 , 1.29]

0.97

[ 0.59 , 1.60]

0.72

[ 0.47 , 1.09]

0.87
1.10

[ 0.55 , 1.35]
[ 0.76 , 1.57]

1.54
1.01

[ 0.81 , 2.95]
[ 0.56 , 1.82]

1.04
1.17

[ 0.60 , 1.81]
[ 0.74 , 1.85]

Cancer Stage
Stage 0/I (Ref.)
Stage II
Stage III
Stage IV

0.89
1.14
0.83

[ 0.65 , 1.22]
[ 0.76 , 1.71]
[ 0.50 , 1.37]

0.78
1.11
0.78

[ 0.47 , 1.31]
[ 0.60 , 2.07]
[ 0.36 , 1.73]

0.83
1.01
0.66

[ 0.55 , 1.25]
[ 0.61 , 1.69]
[ 0.34 , 1.30]

Cancer treatment
Before dep. Dx (Ref.)
After dep dx.
No Treatment

0.95
0.83

[ 0.70 , 1.27]
[ 0.53 , 1.28]

0.40
1.31

[ 0.22 , 0.72]
[ 0.72 , 2.40]

0.51
0.90

[ 0.34 , 0.79]
[ 0.54 , 1.51]

Continued,
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*
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Table 3.4
Adjusted Odds Ratios and 95% Confidence Intervals of Depression Treatment Categories
from Multinomial Logistic Regression on Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression
SEER-Medicare database, 2007-2012
Reference Group = No Depression Treatment
Antidepressants Only
AOR

95%CI

Psychotherapy only
Sig

AOR

Combined AD/Psych

95%CI

Sig

AOR

95%CI

**

1.41

[ 0.75 , 2.68]

1.15

[ 0.82 , 1.63]

Sig

Need factors
Cardiovascular
Yes
No (Ref.)

1.04

[ 0.68 , 1.61]

0.39

[ 0.21 , 0.74]

Musculoskeletal
Yes
No (Ref.)

0.94

[ 0.71 , 1.24]

0.88

[ 0.57 , 1.38]

Respiratory
Yes
No (Ref.)

1.22

[ 0.90 , 1.67]

1.64

[ 1.04 , 2.58]

*

1.20

[ 0.82 , 1.75]

ADRD
Yes
No (Ref.)

1.53

[ 0.98 , 2.40]

2.58

[ 1.44 , 4.61]

**

2.94

[ 1.81 , 4.76]

Anxiety
Yes
No (Ref.)

0.94

[ 0.71 , 1.24]

0.48

[ 0.29 , 0.80]

**

1.17

[ 0.82 , 1.66]

***

External Environment
% Psychologists

0.99

[ 0.96 , 1.02]

1.05

[ 1.00 , 1.11]

*

1.05

[ 1.00 , 1.09]

*

Region
Northeast
south
North-central
West (Ref.)

0.99
1.07
1.27

[ 0.67 , 1.46]
[ 0.77 , 1.51]
[ 0.81 , 1.99]

2.53
0.74
2.27

[ 1.42 , 4.52]
[ 0.39 , 1.39]
[ 1.15 , 4.51]

**

2.48
0.84
2.18

[ 1.56 , 3.95]
[ 0.52 , 1.34]
[ 1.26 , 3.77]

***

0.82

[ 0.64 , 1.05]

0.88

[ 0.59 , 1.33]

1.02

[ 0.75 , 1.40]

Cancer diagnosis
2007-2009 (Ref.)
2010-2012

*

Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study
population characteristics by depression treatment categories, derived from multinomial logistic regression.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
AOR: adjusted odds ratio; AA: African American; ADRD: Alzheimer's disease and related disorders; CI:
Confidence interval; dep: Depression; dx: diagnosis; SEER: Surveillance Epidemiology and End Results;
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**

Sep/div/wid/unkn: Separated/Divorced/Widowed/unknown; SD: Standard deviation; Ref: Reference group; Psych:
psychotherapy.
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Appendix 3.1 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare
Beneficiaries Diagnosed with Incident Breast, Colorectal or Prostate cancer and Newly-diagnosed Depression


Cancer diagnosed identified using Siterwho 1- -10 codes
Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994

Diagnosed with cancer from April 2007 to Dec 2011
Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505






















Diagnosed with cancer from April 2007 to Dec 2011
Primary cancer only in the patient’s lifetime (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate
Incident cases
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783

Elderly with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate
Incident cases, >=66, alive
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585

Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”), Not diagnosed with cancer at
autopsy or death certificate , Incident cases, >=66, alive
Have depression diagnosis
Depression free at cancer diagnosis
Developed newly-diagnosed depression at the 12m follow-up
period
Breast N = 1,805, Colorectal N= 1,433, Prostate N= 1,050

Final Analytical Cohort
Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”), Not diagnosed with cancer at
autopsy or death certificate, Incident cases, >=66, alive, Newlydiagnosed depression.
Fee-for-service continuous enrollment A and B 12m before
depression dxdt and part D 12m after depression dxdt
Breast N = 752, Colorectal N= 550, Prostate N= 371

(N = 1,673)
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Reason for exclusion:
 Not one primary cancer (n=39,257,
n=34,683, n=34,738)
 Diagnosed at autopsy or death cert.
(n=854, n=1,061, n=1,545)
 Not incident cases (n=33,418,
n=30,827, n=32232)

Reasons for exclusion:
 <66 years old (n=47,290, n=23,744,
n=56,295)
 Unknown stage of cancer (n=6,614,
n=4,619, n=10,185)
 Death (n=4,063, n=14,434, n=3,822)

Reasons for exclusion:
 No depression diagnoses (n=65,216,
n=40,934, n=102,155)
 Not depression free at cancer diagnosis
(n=3,810, n=1,774, n=2,340)
 No developed depression during the 12
months follow-up period (n=2,665,n=1,430,
n=2,040)

Reasons for exclusion:
 HMO enrollment and NO Continuous enroll
in Part A & B (n=443, n=461, n=296)
 No Continuous enroll in Part D (n=533,
n=392, n=346)

Appendix 3.2
Adjusted Odds Ratios and 95% Confidence Intervals of Depression Treatment Categories by Cancer Types from
Multinomial Logistic Regression on Depression Treatment Categories Elderly Fee-for-service Medicare beneficiaries
with Breast, Colorectal or Prostate Cancer, SEER-Medicare data from 2007-2012
Antidepressants Only
AOR
95%CI

Sig

Psychotherapy only
AOR
95%CI

Sig

Combined ADs/Psych
AOR
95%CI

Reference Group = Women Breast Cancer
Cancer types
Women Colorectal Cancer
Men Colorectal Cancer
Men Prostate Cancer

0.93
0.87
1.10

[ 0.67 , 1.29]
[ 0.55 , 1.35]
[ 0.76 , 1.57]

0.97
1.54
1.01

[ 0.59 , 1.60]
[ 0.81 , 2.95]
[ 0.56 , 1.82]

0.72
1.04
1.17

[ 0.47 , 1.09]
[ 0.60 , 1.81]
[ 0.74 , 1.85]

0.85
0.61
0.89

[ 0.54 , 1.35]
[ 0.37 , 1.03]
[ 0.48 , 1.65]

Reference Group = Men Prostate Cancer
Women Breast Cancer
Women Colorectal Cancer
Men Colorectal Cancer

0.91
0.85
0.79

[ 0.64 , 1.31]
[ 0.57 , 1.28]
[ 0.48 , 1.30]

0.99
0.96
1.53

[ 0.55 , 1.79]
[ 0.51 , 1.81]
[ 0.74 , 3.18]

Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, Colorectal or prostate cancer and
Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study population
characteristics by depression treatment categories, derived from multinomial logistic regression.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
ADs: Antidepressants; AOR: Adjusted odds ratio; CI: Confidence interval; Psych: Psychotherapy.
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Chapter 4
Depression Treatment and Short-term Healthcare Expenditures
among Elderly Medicare Beneficiaries with Newly-diagnosed Depression and Incident
Breast, Colorectal or Prostate Cancer

4.1 Abstract
Objectives. Depression is associated with high healthcare expenditures and depression treatment
may reduce healthcare expenditures. However, to date there have not been any studies on the
effect of depression treatment on healthcare expenditures among cancer survivors. Therefore, the
purpose of this study is to examine the association between depression treatment and healthcare
expenditures among elderly Medicare beneficiaries with newly-diagnosed depression and
incident breast, colorectal or prostate cancer.
Methods. The current study utilized a retrospective longitudinal study design using the linked
Surveillance, Epidemiology and End Results (SEER)-Medicare database. Elderly (> 66 years)
fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast,
colorectal or prostate cancer (N= 1,502) were followed for a period of 12 months after
depression diagnosis. Healthcare expenditures were measured every month for a period of 12
months after depression diagnosis. Depression treatment was identified during the six months
after depression diagnosis and was categorized into four mutually exclusive categories: 1)
treatment with antidepressants only, 2) treatment with psychotherapy only, 3) combined
treatment with both antidepressants and psychotherapy and 4) no depression treatment. The
adjusted associations between depression treatment and healthcare expenditures were analyzed
with Generalized Linear Mixed Model (GLMM) regressions with gamma distribution and loglink. These regressions controlled for predisposing, enabling, need, and external environmental
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factors. Additionally, the inverse probability weighting technique (IPTW) was used to adjust for
observed selection bias in depression treatment categories.
Results. The average 1-year total healthcare expenditures after depression diagnosis were
$38,219 for those who did not receive depression treatment; $42,090 for those treated with
antidepressants only; $46,913 for those treated with psychotherapy only and $51,008 for those
treated with a combination of antidepressants and psychotherapy. As compared to no depression
treatment, those who received antidepressants had $1,317 higher total healthcare expenditures
those who received psychotherapy had $2,186 higher total healthcare expenditures; and those
who received combination of antidepressants and psychotherapy had $2,754 higher total
healthcare expenditures, after adjusting for selection bias and predisposing, enabling, need, and
external environment factors. The associations between depression treatment and the higher
healthcare expenditures were observed across all types of healthcare expenditures.
Conclusions. Among cancer survivors with newly-diagnosed depression, treatment for
depression was associated with higher short-term healthcare expenditures as compared to no
depression treatment.
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4.2 Introduction
Depression is highly prevalent among cancer survivors and it has been reported that
cancer survivors with depression incur higher healthcare expenditures as compared to those
without depression (1). Among elderly prostate cancer survivors, those with depression had
33.3% higher healthcare expenditures during the 12 months after cancer diagnosis as compared
to those without depression (1). Among adults with cancer, those with depression had 31.7%
higher one-year healthcare expenditures as compared to those without depression (2).
While depression leads to increased healthcare expenditures, depression treatment may
lead to a reduction in healthcare expenditures due to improved health outcomes. However, to
date there have not been any studies that have examined the association between depression
treatment and healthcare expenditures in real-world settings. Therefore, this study infer the
association between depression treatment and healthcare expenditures using findings from
studies among elderly individuals. These studies have shown mixed results on the association
between depression treatment and healthcare expenditures. The Improving Mood-Promoting
Access to Collaborative Treatment (IMPACT) randomized controlled trial (RCT), which
included 418 individuals aged 60 years or older, found that at the end of 24 months the
intervention group had $896 lower expenditures as compared to the usual care group (3). Among
adults with cancer, a RCT found that collaborative care for depression was cost-effective as
compared to usual care (4,5). However, these trials did not compare the healthcare expenditures
of those who received depression treatment to those who did not receive any depression
treatment. A study among elderly fee-for-service Medicare beneficiaries with prevalent
depression and chronic physical conditions seeking care in real-world practice settings found that
treatment for depression with antidepressants (20%) and treatment with psychotherapy
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with/without antidepressants (29%) was associated with an increase in short-term total healthcare
expenditures (6). A longitudinal study in real-world practice settings found that elderly who
received antidepressant treatment had 32% higher outpatient expenditures as compared to those
without antidepressant treatment (Fischer et al., 2002).
The above-mentioned studies suggest that the relationship between depression treatment
and healthcare expenditures is not yet established. To the best of our knowledge, there are no
studies that examine whether depression treatment can reduce healthcare expenditures among
cancer survivors seeking care in real-world settings. It is important to understand the association
between depression treatment and healthcare expenditures for many reasons. First, depression is
associated with poor Health-related Quality of Life (HRQoL), higher healthcare utilization and
expenditures (1,7), and unplanned readmissions (8-10). Depression treatment can improve health
outcomes and may reduce healthcare utilization and expenditures. Understanding this association
is particularly important as a large portion of Medicare healthcare expenditures for cancer
patients is attributed to the treatment of coexisting health conditions (11). Furthermore, Medicare
has implemented many payment reforms to ensure high quality care at lower costs (12). Given
the importance of reducing healthcare spending among Medicare beneficiaries, the current study
can provide important information on comparative effectiveness of depression treatment to
payers, policy makers and providers. The primary objective of the current study is to compare
healthcare expenditures by depression treatment categories among elderly fee-for-service
Medicare beneficiaries with newly-diagnosed depression and incident breast, colorectal or
prostate cancer.
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4.3 Conceptual framework
This study utilized the expanded behavioral model on healthcare utilization, the Andersen
Behavioral Model, to help our selection of the variables that may affect healthcare expenditures
(13). The model suggests that the utilization of health services varies as a function of 1) an
individual’s unique predisposition for using services (predisposing factors – age and race); 2) the
resources available to each individual for obtaining services (enabling factors: cancer type,
cancer stage, cancer treatment, marital status and Primary Care Physican (PCP) visits), 3) the
individual’s need (need factors – depression treatment, the number of chronic physical and
mental health conditions); and 4) the external environment: SEER region and year of cancer
diagnosis.
4.4. Methods
4.4.1 Design
This study utilized a retrospective longitudinal study design with a 12-month baseline
(April 2006 through December 2011) and a 12-month follow-up period (April 2007 through
December 2012). The baseline period was based on depression diagnosis date and consisted of
the 12 months before the depression diagnosis date. Healthcare expenditures were measured
every month for a period of 12 months after depression diagnosis. To capture the variations in
healthcare expenditures at different time point of follow-up period. This study used the repeated
measures statistical models. As independent measure design often measure aggregated healthcare
expenditures at the follow-up period, repeated measures were used because it allowed us to
capture the expenditures during and after depression treatment.
Depression treatment was measured during the first six months after depression
diagnosis. Other explanatory variables were measured during the 12-months before depression
diagnosis and during the follow-up period.
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4.4.2 Data Sources
The current study linked data from several sources including the SEER-Medicare linked
database, ACS estimates from census, and the AHRF files. The detailed description of the data
sources are provided in Chapter 1.
4.4.3 Study population
The study population is composed of elderly cancer survivors (age > 66 years) who were
diagnosed with incident breast, colorectal or prostate cancer and who were newly-diagnosed with
depression after cancer diagnosis between 2007 and 2011. This study identified the cancer types
(breast, colorectal or prostate cancer) using the International Classification of Diseases for
Oncology, 3rd Edition (ICD-O-3) histology codes and the primary site variable.

Cancer Survivors with newly-diagnosed depression
This study identified cancer survivors with newly-diagnosed depression based on the
National Committee on Quality Assurance (NCQA) criteria (15). To achieve this, a depressionfree cancer cohort with incident cancer diagnosis between April 2007 and December 2011 was
first established. This study used a validated algorithm to identify newly-diagnosed depression
after cancer diagnosis by including only those who were diagnosed with depression after cancer
diagnosis and who did not have any antidepressant use 90 days prior to depression diagnosis
(16). This study used the following codes from the International Classifications of Diseases – 9th
edition, Clinical Modification (ICD-9-CM): 296.2, 296.3, 298.0, 300.4, 309.1 and 311.0. These
codes are widely used to identify depression diagnoses in Medicare beneficiaries (1,17,18).
Inclusion/exclusion criteria
This study required that all individuals have continuous enrollment in Medicare part A, B
and no enrollment in Medicare managed care plans during the baseline and follow-up periods.
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This study also required that individuals have continuous enrollment in Medicare part D during
three months prior to and 12 months after depression diagnosis in order to identify depression
treatment in the follow-up period. This study excluded individuals with unknown cancer stage at
diagnosis, those diagnosed through autopsy or death certificate, or those who died during the
follow-up period. Appendix 1.1 summarizes the analytical population selection process. The
final study population consisted of 1,502 elderly Medicare beneficiaries with newly-diagnosed
depression and incident breast, colorectal or prostate cancer.
4.4.4 Dependent Variables
Type and Total Healthcare Expenditures
Healthcare expenditures were derived from the Medicare claims files and included the
amount paid by Medicare. This study identified the type of healthcare expenditure based on
whether the services were provided in an inpatient, outpatient, prescription drug or home
healthcare setting. The following types of healthcare expenditures were analyzed; inpatient,
outpatient, prescription drugs, and other. Other expenditures consisted of DME and HHA
expenditures. Total healthcare expenditures were derived as the sum of inpatient, outpatient,
prescription drugs, durable medical equipment and home health agency expenditures.
Total and type of healthcare expenditures were classified into yearly and monthly
expenditures during the follow-up period. Yearly expenditures consisted of expenditures for the
entire 12-month period after depression diagnosis. Monthly expenditures were calculated for
every month after depression diagnosis. All healthcare expenditures were adjusted by the
Consumer Price Index and expressed in 2012 constant dollars.
4.4.5 Key Independent Variable
The key independent variable was the depression treatment during the first six months
after depression diagnosis. Antidepressant use was derived from Medicare Part D claims using
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the National Drug Codes (NDC) and generic names. Antidepressants included selective serotonin
reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), tricyclic
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and others (mirtazapine,
bupropion). Any cancer survivor with at least one prescription for antidepressants was
considered to be using antidepressants. Psychotherapy visits were derived from Medicare
outpatient claims using the Current Procedural Terminology (CPT) codes.
Based on antidepressant use and psychotherapy visits, depression treatment was
categorized into four mutually exclusive categories: (1) treatment with antidepressants only:
individuals received, at least, one prescription of antidepressants and no psychotherapy visits; (2)
treatment with psychotherapy only: individuals had, at least, one psychotherapy office visit and
no prescription for antidepressants; (3) both antidepressants and psychotherapy: individuals
received, at least, one prescription for antidepressants with at least one psychotherapy visit; (4)
no treatment: individuals received no antidepressants and no psychotherapy.
4.4.6 Other Independent Variables
Time-Invariant Variables
These variables were measured during the baseline period (i.e. 12 months before
depression diagnosis). Predisposing characteristics included age in years at cancer diagnosis
(66-69, 70-74, 75-79, >=80) and race (White, African American, and others). Enabling factors,
included marital status (married, divorced/separated/widowed, and never married), cancer types
(women with breast cancer, women with colorectal cancer, men with colorectal cancer, men with
prostate cancer); and stage at cancer diagnosis, categorized using the American Joint Committee
on Cancer (AJCC) grouped staging (stage 0/I, stage II, and stage III/ IV). Need factors composed
of the number of chronic physical and mental health conditions during the baseline period.

94

External environmental characteristics included SEER region (Northeast, South, North-central,
and West) and the year of cancer diagnosis.
Time-varying independent variables
These were measured every month during the follow-up period (i.e. 12-months after
depression diagnosis) and included PCPs visits and cancer treatment (chemotherapy, radiation
therapy or surgery).
4.5 Statistical Analysis
Bivariate Analyses
T-tests and F-tests were used to examine the unadjusted differences in average healthcare
expenditures by depression treatment categories. Mean, standard deviation and median were
used to describe healthcare expenditures by depression treatment categories.
Analyses with repeated measures
As healthcare expenditures were measured for every month during the follow-up period,
each individual had 12 observations. These 12 observations were not independent, so standard
regression techniques can not be applied. Therefore, the associations between depression
treatment and total healthcare expenditures were analyzed with a repeated measures design using
Generalized Mixed Linear Model (GLMM) regressions with gamma distribution and log link.
The GLMM model was selected because this study found that 65% of the variation in healthcare
expenditures was due to differences within individuals. GLMM regressions account for
correlated error terms due to repeated measures from the same person. In these regressions,
predisposing, enabling and need factors affecting depression treatment as well as external
environmental characteristics were included. Based on the regression co-efficient estimates,
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expenditures associated with depression treatment categories, as compared to no depression
treatment, were calculated.
Observed Selection Bias: Adjusting for inverse probability weighting technique (IPTW)
The inverse probability weighting technique (IPTW) was used to adjust for observed
group differences in depression treatment categories. The IPTW approach calculates weight for
each individual based on the inverse of their propensity to receive a specific type of depression
treatment or no treatment. Under this approach, individuals with lower propensity will be upweighted and those with higher propensity will be down-weighted. This helps balance the
probability of treatment across the treatment groups. In order to account for the differences in
group sizes of the treatment groups, the weights were further stabilized by dividing them with the
sample size of each treatment group.
4.6 Results
4.6.1 Characteristics of the study population
The study population consisted of 1,502 elderly fee-for-service Medicare beneficiaries
with incident breast, colorectal or prostate cancer who had newly-diagnosed depression after
cancer diagnosis. In this study population, 45.0% were women with breast cancer, 22.8% were
women with colorectal cancer, 10.1% were men with colorectal cancer and 22.1% were men
with prostate cancer. Also, this study found that 47.4% received antidepressants only, 9.3%
received psychotherapy only, 18.9% received both antidepressants and psychotherapy and 24.4%
did not receive any depression treatment. The description of time-invariant and time-varying
explanatory variables by depression treatment categories are presented in Tables 1 and 2
respectively.
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4.6.2 IPTW-adjusted Yearly Healthcare Expenditures by Depression Treatment Categories
Table 3 summarizes the average 1-year expenditures for depression treatment categories.
The mean 1-year total healthcare expenditures after depression diagnosis were $38,219 for those
who did not receive depression treatment, $42,090 for those treated with antidepressants only,
$46,913 for those treated with psychotherapy only and $51,008 for those treated with a
combination of antidepressants and psychotherapy. Average 1-year total healthcare expenditures
were significantly higher for those treated with a combination of antidepressants and
psychotherapy (p value< 0.001). Also, the average 1-year inpatient and prescription drugs
healthcare expenditures after depression diagnosis were significantly higher for those treated
with a combination of antidepressants and psychotherapy (p value< 0.001).
4.6.3 IPTW-Adjusted Generalized Mixed Linear Models of Monthly Expenditures
As compared to no depression treatment, depression treatment with antidepressants only
was associated with a $1,317 increase in total healthcare expenditures, treatment with
psychotherapy only was associated with a $2,186 increase while treatment with combination of
antidepressants and psychotherapy was associated with $2,754 increase. As compared to no
therapy, this study found that treatment with antidepressants only, psychotherapy only, and the
combination of antidepressants and psychotherapy were associated with high inpatient,
outpatient and other healthcare expenditures as compared to no therapy (Table 4).
4.6.4 Sensitivity Analyses
To ensure robustness of the association between depression treatment categories and
healthcare expenditures, sensitivity analyses were conducted. These included healthcare
expenditures without repeated measures (i.e. measuring 1-year healthcare expenditures), mixed
effect linear models with log-transformed healthcare expenditures (Tables 4 and 5), and
instrumental variable regressions that controlled for unobserved selection bias. In the
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instrumental variable regression, the percentage of psychologists at the county-level was used as
an instrument and depression treatment was considered as endogenous. Across all models and
even after controlling for the unobserved selection bias, depression treatment was associated
with higher expenditures as compared to no depression treatment. For example, depression
treatment with psychotherapy only was associated with higher total healthcare expenditures as
compared to no depression treatment in the GLMM model (Beta: 0.31; SE:0.07), the Mixed
Linear model with log-transformed expenditures (Beta: 0.40; SE:0.10), the adjusted 1-year
healthcare expenditures model (Beta: 0.31; SE:0.08) and in the instrumental variable regression
model (Beta: 0.01; SE:0.01). Depression treatment with antidepressants only was associated with
higher total healthcare expenditures as compared to no depression treatment in the GLMM
model (Beta: 0.20; SE:0.04), the Mixed Linear model with log-transformed expenditures (Beta:
0.38; SE:0.06), the adjusted 1-year healthcare expenditures model (Beta: 0.13; SE:0.07) and in
the instrumental variable regression model (Beta: 0.02; SE:0.01). Depression treatment with a
combination of antidepressants and psychotherapy was associated with higher total healthcare
expenditures as compared to no depression treatment in the GLMM model (Beta: 0.38; SE:0.05),
the Mixed Linear model with log-transformed expenditures (Beta: 0.68; SE:0.07), the adjusted 1year healthcare expenditures model (Beta: 0.31; SE:0.08) and in the instrumental variable
regression model (Beta: 0.12; SE:0.02).

4.7 Discussion
The current study examined the association between depression treatment categories and
healthcare expenditures among elderly Medicare beneficiaries with newly-diagnosed depression
and incident breast, colorectal or prostate cancer. To date, the current study is the first one to
analyze the association between depression treatment categories and healthcare expenditures.
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The study findings suggest that depression treatment was associated with an increase in shortterm healthcare expenditures as compared to no depression treatment. Our results are consistent
with the one published study on depression treatment and expenditures among elderly with
chronic physical conditions, which found that depression treatment with antidepressants or
psychotherapy was associated with increase in short-term healthcare expenditures (6). The
positive association between depression treatment and healthcare expenditures was robust and
persisted even after adjustment for other factors and across different model specifications.
The positive association between depression treatment categories and healthcare
expenditures among cancer survivors has many plausible explanations. There is evidence of
depression treatment failure in many individuals. For example, the STAR*D (Sequenced
Treatment Alternatives to Relieve Depression) trial found that only one-third of patients get
relief for their depressive symptoms with depression treatment (19). Therefore, there may be
many cancer survivors who did not respond to depression treatment, which may have resulted in
poor health outcomes and increased healthcare expenditures. However, this study did not
measure if those who received depression treatment responded to their therapy or not. It is also
known that adequate depression treatment is critical in improving health outcomes. A study
among adults found that adherence to antidepressant medication treatment for at least 90 days
reduced healthcare expenditures (20). However, our study did not measure the adequacy of
depression treatment or adherence to depression treatment. Therefore, future studies need to
explore the relationship between adherence to depression treatment and healthcare expenditures
among cancer survivors. It is also plausible that under fee-for-service healthcare systems, many
individuals with both physical and mental health conditions receive fragmented care and such
fragmented care may result in increased expenditures regardless of treatment for depression.

99

Our findings have significant policy implications. This study estimated the average
healthcare expenditures over a 12-month period among elderly Medicare with newly-diagnosed
depression and incident cancer. Therefore, these estimates can be considered as expenditures
following a new episode of depression in elderly with incident cancer. Such estimates have an
important implication for Accountable Care Organization’s (ACO’s) Medicare Shared Saving
Programs for risk adjustment while also setting the expected expenditure benchmark for
individuals with cancer and newly-diagnosed depression. Also, our study findings have
implications for the Centers for Medicare and Medicaid Services’s new bundled payment models
as well as a new payment and delivery model, the Oncology Care Model (OCM), which aims to
improve the quality of care and care coordination while lowering costs for patients receiving
chemotherapy. Our findings can help these payment models in building the quality metrics that
providers must achieve to maximize their payment.
Further, our study findings also have clinical practice implications. It has been shown that
collaborative care rather than usual care for depression leads to a reduction in depressive
symptoms and decreases expenditures (21). As compared to usual care, the SMaRT Oncology2 (Symptom Management Research Trial, Oncology-2) found that integrated collaborative
treatment for depression among cancer patients was associated with higher remission rates as
compared to usual care treatment for depression (4,5). This trial also found that depression
treatment delivered within a collaborative care model was cost-effective (4,5). Our findings
suggest that treating depression in the usual care setting may not be sufficient to achieve lower
costs and collaborative care models may need to become standard clinical practice. In this
context, it may be important to enroll Medicare beneficiaries with cancer and newly-diagnosed
depression into patient-centered medical homes which have many elements of collaborative care
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including the use of evidence-based treatment of depression, collaboration between health care
providers and monitoring depression treatment adherence (22,23).
Our study has many strengths; it is the first that has examined the impact of depression
treatment on total healthcare expenditures in real-world fee-for-service settings. The use of
SEER-Medicare data allowed us to use a longitudinal study design and follow patients for a long
period of time across different providers. Data from Medicare Part D enabled us to identify
pharmacological therapy for depression and include expenditures related to prescription drugs.
This study also tested the robustness of the relationship between depression treatment and
healthcare expenditures using various model specifications. The current study has some
limitations: the SEER-Medicare data are not developed for research purposes and therefore have
limitations associated with its use for estimating total healthcare expenditures. This study only
observed filled antidepressant prescriptions and not antidepressant use. The study findings
cannot be generalizable to all Medicare beneficiaries because the study population is restricted to
those residing in SEER regions and to those with fee-for-service Medicare plans. Another
limitation related to the observational study was the selection bias, although the observable and
unobservable selection bias were controlled using the inverse probability weighting technique
and the instrumental variables approach these biases cannot be completely eliminated.
4.8 Conclusions
Our study has provided new evidence for the literature on the impact of depression
treatment on healthcare expenditures among elderly fee-for-service Medicare beneficiaries with
newly-diagnosed depression and incident cancer seeking care in real-world clinical practice
settings. This study found that treatment for depression was associated with higher short-term
healthcare expenditures as compared to no depression treatment. Our findings were robust to
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different model specifications, even after adjusting for observed and non-observed selection bias.
Future studies may need to examine whether factors such as adequacy of depression treatment
and adherence to treatment among cancer survivors can lead to reduction in short-term
healthcare expenditures.
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Table 4.1
Description of the Study Population by Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer
SEER-Medicare Database, 2007-2012
No
Combine AD
Depression
Total
AD only
Psych only
& Psych
Treatment
Total

N

%

N

%

N

%

N

%

N

%

1,673

100.0

712

47.4

139

9.3

284

18.9

367

24.4

sig

Predisposing factors
Age in years
66-69
70-74
75-79
>=80
Race
White
AA/others

388
389

25.8
25.9

194
186

50.0
47.8

37
33

9.5
8.5

73
66

18.8
17.0

84
104

21.6
26.7

313
412

20.8
27.4

150
182

47.9
44.2

22
47

7.0
11.4

62
83

19.8
20.1

79
100

25.2
24.3
***

1244
258

82.8
17.2

619
93

49.8
36.0

107
32

8.6
12.4

231
53

18.6
20.5

287
80

23.1
31.0

Enabling factors
Marital Status
Married

***
578

38.5

282

48.8

37

6.4

103

17.8

156

27.0

163
669

10.9
44.5

62
368

38.0
48.4

24
78

14.7
10.2

45
136

27.6
17.9

32
179

19.6
23.5

676
343

45.0
22.8

338
155

50.0
45.2

55
37

8.1
10.8

122
66

18.0
19.2

161
85

23.8
24.8

Prostate

151
332

10.1
22.1

67
152

44.4
45.8

20
27

13.2
8.1

27
69

17.9
20.8

37
84

24.5
25.3

Cancer Stage
Stage 0-I
Stage II

524
649

34.9
43.2

258
299

49.2
46.1

45
58

8.6
8.9

98
128

18.7
19.7

123
164

23.5
25.3

Stage III/IV

329

21.9

155

47.1

36

10.9

58

17.6

80

24.3

Never married
Sep/div/wid/Unkn
Cancer type
Breast
Women colorectal
Men colorectal

Need factors
# Physical Conditions
(mean (SD))

3.05 (1.65)

2.94 (1.59)

3.15 (1.84)

3.43 (1.65)

2.91 (1.66)

# Mental Conditions
(mean (SD))

7.54 (0.65)

7.59 (0.58)

7.54 (0.71)

7.36 (0.80)

7.58 (0.60)

External Environment
***

Region
Northeast

294

19.6

116

39.5

39

13.3

81

27.6

58

19.7

south

418

27.8

228

54.5

23

5.5

57

13.6

110

26.3

Continued,
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Table 4.1
Description of the Study Population by Depression Treatment Categories Elderly Fee-for-service Medicare
beneficiaries with newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer
SEER-Medicare Database, 2007-2012
No
Combine AD
Depression
Total
AD only
Psych only
& Psych
Treatment
North-central
West
Cancer diagnosis year
2007-2009
2010-2012

N

%

N

%

N

%

N

%

N

%

189
601

12.6
40.0

85
283

45.0
47.1

23
54

12.2
9.0

46
100

24.3
16.6

35
164

18.5
27.3

913
589

60.8
39.2

445
267

48.7
45.3

87
52

9.5
8.8

167
117

18.3
19.9

214
153

23.4
26.0

Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and B during
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study
population characteristics by depression treatment categories, derived from chi-square statistics.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
Physical conditions included diabetes, heart disease, hyperlipidemia, hypertension, stroke, arthritis, osteoporosis,
asthma and chronic obstructive pulmonary disorder. Mental conditions included Alzheimer and other related
disorders, anxiety, and other mental disorders.
AA: African American; AD: Antidepressants; Psych: Psychotherapy; SEER: Surveillance Epidemiology and End
Results; Sep/div/wid/unkn: Separated/Divorced/Widowed/unknown; SD: Standard deviation.

106

sig

Table 4.2
Description of Time Varying Independent Variables for the Study Population by Depression Treatment
Categories Elderly Fee-for-service Medicare beneficiaries
with Newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer
SEER-Medicare Database, 2007-2012
Combine AD
No Depression
Total
AD only
Psycho only & Psych
Treatment
N

%

N

%

N

%

N

%

N

%

18,024

100.0

6,476

35.9

677

3.8

660

3.7

10,211

56.7

1,860
16,164

10.3
89.7

707
5,769

38
35.7

55
622

3.0
3.8

49
611

2.6
3.8

1,049
9,162

56.4
56.7

Radiation Therapy
Yes
No

947
17,077

5.3
94.7

357
6,119

37.7
35.8

28
649

3.0
3.8

32
628

3.4
3.7

530
9,681

56.0
56.7

Surgery
Yes
No

450
17,574

2.5
97.5

153
6,323

34.0
36.0

25
652

5.6
3.7

14
646

3.1
3.7

258
9,953

57.3
56.6

PCP visits
(mean(SD))

1.49 (0.50)

Total
Chemotherapy
Yes
No

sig
**

1.46 (0.50)

1.38 (0.49)

1.36 (0.48)

1.52 (0.50)

Note: Based on 12 repeated measures for 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed
depression and incident breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and
B during the observation period and Part D during the follow-up period. Asterisks represent significant differences
in study population characteristics by depression treatment categories, derived from chi-square statistics.
*** p < .001; **.001 ≤ p < .01; *.01 ≤ p < .05.
AD: Antidepressants; Psych: Psychotherapy; PCP: Primary Care Provider; SEER: Surveillance Epidemiology and
End Results; SD: Standard deviation.
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Table 4.3
IPTW adjusted Mean Expenditures by Depression Treatment Categories Elderly
Fee-for-service Medicare beneficiaries with Newly-diagnosed Depression and Incident Breast,
colorectal, or Prostate Cancer
SEER-Medicare database, 2007-2012
Mean $ (SE)
sig Mean $ (SE)
sig
Mean $ (SE)
sig Mean $ (SE)
sig
Combine AD &
No Depression
AD only (N= 712)
Psycho only (N= 139) Psych (N= 284)
Treatment (N = 367)
Total Healthcare Expenditures
42,090 (2,805)
46,913 (4,615)
51,008 (3,530) ***
38,217 (2,227)
Outpatient Expenditures
16,812 (1,062)
17,165 (1,748)
15,571 (1,337)
14,815 (844)
Inpatient Expenditures
18,039 (2,160)
22,344 (3,554)
27,040 (2,718) ***
18,012 (1,716)
Prescription Drugs Expenditures
4,787 (299) ***
3,584 (493)
5,674 (377) ***
3,340 (238)
Other Expenditures
2,451 (312)
3,821 (513) ***
2,724 (392)
2,053 (247)
Among Users of Inpatient and Other Services
Inpatient Expenditures
Combine AD &
No o Depression
AD only (N= 399)
Psycho only (N= 76)
Psych (N= 189)
Treatment (N = 202)
31,692 (3,299)
41,902 (5,561)
40,910 (3,973)
*
31,789 (2,623)
Prescription Drugs Expenditures
Combine AD &
No Depression
AD only (N= 712)
Psycho only (N= 136) Psych (N= 284)
Treatment (N = 361)
4,787 (301) ***
3,660 (498)
5,674 (379) ***
3,389 (240)
Other Expenditures
Combine AD &
No o Depression
AD only (N= 441)
Psycho only (N= 94)
Psych (N=167)
Treatment (N 222)
3,978 (456)
5,102 (713)
*
4,653 (595)
*
3,292 (369)

Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and B and Part D during the
observation period.
Total healthcare expenditures were the sum of inpatient, outpatient, prescription drug, durable medical equipment,
and home health agency expenditures. Other expenditures consisted of durable medical equipment and home health
agency.
Asterisks indicate statistical significance the average healthcare expenditures by depression treatment categories
based on T-tests.
***p <.001; **.001 ≤ p < .01; *.01 ≤ p < .05.
AD: Antidepressants; Psych: Psychotherapy; N: Number; SEER: Surveillance Epidemiology and End Results; SD:
Standard deviation.
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Table 4.4
Parameter Estimates of Depression Treatment Categories From GLMM and Mixed Effects linear Model
On Monthly Healthcare Expenditures, Elderly Fee-for-service Medicare Beneficiaries with Newlydiagnosed Depression and Incident Breast, Colorectal or Prostate Cancer
SEER-Medicare Database, 2007-2012
Generalized Mixed Linear Model with gamma distribution and log-link
(Reference Group for Depression Treatment = No Depression Treatment)

Total
Outpatient
Inpatient
Prescription Drugs
Other

Intercept
(SE)
8.70***
(0.11)
7.06***
(0.09)
9.13***
(0.38)
5.34***
(0.08)
5.63***
(0.27)

AD only
(SE)
0.20***
(0.04)
0.13**
(0.04)
0.56**
(0.17)
0.33**
(0.03)
0.21*
(0.10)

Change#
$1,137
$164
$6,906
$82
$66

Psych
only (SE)
0.31 ***
(0.07)
0.23 ***
(0.06)
0.88 **
(0.34)
0.12 *
(0.05)
0.59 **
(0.18)

Change#
$2,186
$302
$13,139
$26
$224

AD &
Psych (SE)
0.38***
(0.05)
0.26***
(0.05)
0.51**
(0.18)
0.53***
(0.04)
0.21
(0.13)

Change#
$2,754
$340
$6,195
$146
$65

Mixed Linear Model with Log-transformed Expenditures
(Reference Group for Depression Treatment = No Depression Treatment)

Total
Outpatient
Inpatient
Prescription Drugs
Other

Intercept
(SE)
6.91***
(0.15)
6.86***
(0.16)
1.82***
(0.18)
4.00***
(0.19)
0.48*
(0.20)

AD only
(SE)
0.38***
(0.06)
0.18**
(0.07)
0.03
(0.06)
0.77***
(0.09)
0.09
(0.09)

%
Change
38%
18%
3%
77%
9%

Psych
only (SE)
0.42 ***
(0.10)
0.52 ***
(0.11)
0.08
(0.10)
-0.16
(0.17)
0.25
(0.17)

%
Change
42%
52%
8%
16%
25%

AD &
Psych (SE)
0.68***
(0.07)
0.58***
(0.09)
0.25**
(0.08)
0.77***
(0.11)
0.03
(0.12)

%
Change
68%
58%
25%
77%
3%

Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A, B, and D during the
observation period. Other expenditures consisted of durable medical equipment and home health agency costs. Total
healthcare expenditures consisted of inpatient, outpatient, prescription drug, durable medical equipment, and home
health agency expenditures.
# Change was calculated by first exponentiating the intercept term to calculate the expenditures for no depression
treatment. Then, the sum of the intercept and the parameter estimate for depression treatment type were
exponentiated to get the expenditures for depression treatment. The differences in these two estimates was reported
as the change in healthcare expenditures associated with depression treatment.
% change in expenditures was calculated by exponentiating the parameter estimate and subtracting one (eβ−1).
Models adjusted for time in months, depression treatment, age, race/ethnicity, marital status, PCP visits during each
month of follow-up, cancer type, cancer treatment during each month of follow-up, cancer stage, and number of
physical and mental conditions, SEER region, Year of cancer diagnosis. Asterisks indicate significant differences
by depression categories as compared to no depression treatment based on GLMM regressions and Mixed linear
model regressions on healthcare expenditures.
***P <.001; **.001 ≤ P < .01; *.01 ≤ P < .05.
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AD: Antidepressants; IPTW: Inverse Probability Treatment Weights; Psych: Psychotherapy; SE: Standard Error;
SEER: Surveillance Epidemiology and End Results
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Table 4.5
Parameter Estimates of Depression Treatment Categories from Generalized Linear Models on One-year
Healthcare Expenditures Elderly Fee-for-service Medicare beneficiaries with newly-diagnosed Depression
and Incident Breast, colorectal, or Prostate Cancer
SEER-Medicare Database, 2007-2012
IPTW Adjusted Generalized Linear Model with gamma distribution and Log link
(Reference Group for Depression Treatment = No Depression Treatment)

Total
Outpatient
Inpatient
Prescription Drugs
Other

Intercept
(SE)
9.70***
(0.41)
8.17***
(0.41)
8.95***
(0.68)
7.48***
(0.36)
6.68***
(0.84)

AD only
(SE)
0.13
(0.07)
0.14*
(0.07)
0.06
(0.13)
0.33***
(0.08)
0.21
(0.13)

%
Change
$2,265
$581
$477
$693
$188

Psych
only (SE)
0.25*
(0.13)
0.22
(0.12)
0.33
(0.21)
0.09
(0.13)
0.47*
(0.21)

%
Change
$4,635
$951
$3,014
$167
$478

AD &
Psych (SE)
0.31***
(0.08)
0.12***
(0.07)
0.41**
(0.14)
0.54***
(0.09)
0.18
(0.17)

%
Change
$5,930
$493
$3,906
$1,269
$157

Unadjusted Generalized Linear Model with gamma distribution and Log link
(Reference Group for Depression Treatment = No Depression Treatment)

Total
Outpatient
Inpatient
Prescription Drugs
Other

Intercept
(SE)
9.32***
(0.34)
8.10***
(0.34)
8.35***
(0.62)
7.21***
(0.34)
6.19***
(0.79)

AD only
(SE)
0.13*
(0.07)
0.12
(0.06)
0.06
(0.13)
0.33***
(0.08)
0.20
(0.13)

%
Change
$1,549
$420
$262
$529
$108

Psych
only (SE)
0.27*
(0.11)
0.20*
(0.10)
0.35
(0.21)
0.22
(0.12)
0.48*
(0.19)

%
Change
$3,459
$729
$1,773
$333
$301

AD &
Psych (SE)
0.33***
(0.08)
0.10
(0.07)
0.44**
(0.14)
0.55***
(0.08)
0.20
(0.17)

%
Change
$4,363
$346
$2,338
$992
$188

Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A, B, and D during the
observation period. Other expenditures consisted of durable medical equipment and home health agency costs. Total
healthcare expenditures consisted of inpatient, outpatient, prescription drug, durable medical equipment, and home
health agency expenditures.
% change in expenditures was calculated by exponentiating the parameter estimate and subtracting one (eβ−1).
Models adjusted for depression treatment, age, race/ethnicity, marital status, PCP visits, cancer type, cancer
treatment, cancer stage, and number of physical and mental conditions, SEER region, Year of cancer diagnosis.
Asterisks indicate significant differences by depression categories as compared to no depression treatment based on
GLM regressions on one-year healthcare expenditures.
***P <.001; **.001 ≤ P < .01; *.01 ≤ P < .05.
AD: Antidepressants; IPTW: Inverse Probability Treatment Weights; Psych: Psychotherapy; SE: Standard Error;
SEER: Surveillance Epidemiology and End Results.

111

Appendix 4.1 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare
Beneficiaries Diagnosed with Incident Breast, Colorectal or Prostate cancer and Newly-diagnosed Depression



Cancer diagnosed identified using Siterwho 1- -10 codes
Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994

Diagnosed with cancer from April 2007 to Dec 2011
Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505






















Diagnosed with cancer from April 2007 to Dec 2010
Primary cancer only in the patient’s lifetime (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate
Incident cases
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783

Elderly with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”)
Not diagnosed with cancer at autopsy or death certificate
Incident cases, >=66, alive
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585

Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”), Not diagnosed with cancer at
autopsy or death certificate , Incident cases, >=66, alive
Have depression diagnosis
Depression free at cancer diagnosis
Developed newly-diagnosed depression from April 2007-Dec 2011
Breast N = 1,662, Colorectal N= 1,351, Prostate N= 973

Final Analytical Cohort
Diagnosed with cancer from April 2007 to Dec 2011
With primary cancer (Seq1 in “00”), Not diagnosed with cancer at
autopsy or death certificate, Incident cases, >=66, alive, Newlydiagnosed depression.
Fee-for-service continuous enrollment A and B 12m before
depression diagnosis and part D 12m after depression diagnosis
Breast N = 676, Colorectal N= 494, Prostate N= 332

(N = 1,502)
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Reason for exclusion:
 Not one primary cancer (n=39,257,
n=34,683, n=34,738)
 Diagnosed at autopsy or death cert.
(n=854, n=1,061, n=1,545)
 Not incident cases (n=33,418,
n=30,827, n=32232)

Reasons for exclusion:
 <66 years old (n=47,290, n=23,744,
n=56,295)
 Unknown stage of cancer (n=6,614,
n=4,619, n=10,185)
 Death (n=4,063, n=14,434, n=3,822)

Reasons for exclusion:
 No depression diagnoses (n=65,216,
n=40,934, n=102,155)
 Not depression free at cancer diagnosis
(n=3,810, n=1,774, n=2,340)
 No developed depression during the 12
months follow-up period (n=2,665,n=1,430,
n=2,040)

Reasons for exclusion:
 HMO enrollment and NO Continuous enroll
in Part A & B 12 months after depression
diagnosis (n=399, n=401, n=264)
 No Continuous enroll in Part D 12 month after
depression diagnosis (n=210, n=441, n=366)

CHAPTER 5
SUMMARY AND CONCLUSIONS
5.1 Study Summary and Discussion
This study set out to investigate a new and emerging area of research in the management
of multiple chronic conditions, specifically the presence and management of depression among
elderly cancer survivors. While there is a substantial literature on the prevalence of depression
and its negative impact on health outcomes in cancer, issues related to the incidence and
treatment of newly-diagnosed depression have received much less attention. Only recently,
interest has emerged in the ways that treatment of one condition (e.g., depression) influences
outcomes and costs associated with another condition (e.g., cancer). To date, there have not been
any studies on variations in the risk of newly-diagnosed depression among cancer types. Also,
there are no studies on depression treatment and its impact on healthcare expenditures among
cancer survivors. Our work will be a landmark study in this new generation of research. It will
point clinicians to opportunities for improved cancer outcomes, and policy-makers to potential
cost-saving strategies.
This dissertation focused on answering three related research questions: (1) what is the
variation in the risk of newly-diagnosed depression by cancer types among elderly cancer
survivors with incident breast, colorectal or prostate cancer, (2) what are the depression
treatment rates and what factors affect treatment in cancer survivors and (3) what impact does
this depression treatment have on healthcare expenditures among cancer survivors? Breast,
colorectal and prostate cancers were selected as they are the most common types of cancer in
which depression is highly prevalent.

113

Although there is evidence that all cancer survivors are at risk for developing depression
as compared to matched non-cancer cohorts, it is unknown if there are variations in the risk of
depression between different cancer types. For example, it is possible that some cancer types
have a higher risk of depression due to poor survival rates or the late stage at which that type of
cancer is diagnosed. Identifying these variations can help to determine which cancer survivors
might have a higher risk of depression, thus identifying who can benefit from routine depression
screening and monitoring to help in early detection and treatment of depression. Therefore, the
first aim of this study was to evaluate the relationship between cancer types and the risk of
newly-diagnosed depression with the following comparisons: women with breast cancer were
compared to women with colorectal cancer while men with prostate cancer were compared to
men with colorectal cancer.
It was observed that elderly women with colorectal cancer had a higher risk of newlydiagnosed depression as compared to elderly women with breast cancer while elderly men with
colorectal cancer had a higher risk of newly-diagnosed depression as compared to elderly men
with prostate cancer. The highest rates of newly-diagnosed depression among colorectal cancer
survivors, who are typically diagnosed at a later stage, suggest that cancer survival prognosis
may affect the risk of developing depression. This study found that cancer survivors with a latestage diagnosis were more likely to be diagnosed with depression as compared to those with an
early-stage diagnosis. This finding suggests that stage at cancer diagnosis can affect the risk of
developing depression. Further, this study found that cancer survivors who had a higher number
of primary care visits had a higher rate of newly-diagnosed depression as compared to those with
fewer primary care visits. Therefore, primary care providers may play an important role in the
recognition of depression among elderly cancer survivors.
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While diagnosing depression is the first step, treating depression with either
antidepressants, psychotherapy or combined antidepressants and psychotherapy is the next
critical step to reduce depressive symptoms and improve the clinical outcomes of cancer
survivors. Even though clinical guidelines recommend depression treatment for cancer survivors
regardless of cancer types or stage at cancer diagnosis (1,2), elderly cancer survivors may be
undertreated for depression because cancer is often considered the dominant condition and it
“eclipses” the management of depression. While there is some research on depression treatment
rates among cancer survivors with prevalent depression, there are no studies on the rates of
depression treatment among cancer survivors with newly-diagnosed depression. Therefore, the
second aim of this study was to estimate depression treatment rates among cancer survivors and
to examine the factors that affect depression treatment among elderly with newly-diagnosed
depression and incident breast, colorectal or prostate cancer.
This study found that nearly 27% of cancer survivors with newly-diagnosed depression
did not receive any treatment for depression. The majority of the study population received
antidepressants only to treat newly-diagnosed depression. This study also found that ongoing
cancer treatment after depression diagnosis was associated with lower rates of depression
treatment. This finding suggests that the competing demand to treat cancer affects the
management of depression. Also, individuals with a higher number of primary care provider
visits were more likely to receive psychotherapy or a combination of antidepressants and
psychotherapy. This indicates the importance of primary care providers in the management of
depression. Further, there is evidence that a higher county-level percentage of psychologists was
associated with a higher use of psychotherapy and a higher use of combination of
antidepressants and psychotherapy. In other words, this study found that the supply of mental
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healthcare providers is important in receiving depression treatment. Another finding was that
there are racial disparities in depression treatment. African American and other racial minorities
were less likely to receive antidepressant treatment. This suggests that there is a need to reduce
racial disparities in depression treatment.
Depression treatment can improve clinical as well as economic outcomes for cancer
survivors. However, the economic benefits of treating depression have not been evaluated
previously in cancer survivors. Evidence from real-world clinical practice studies among elderly
with chronic conditions have suggested that depression treatment for prevalent depression can
increase short-term healthcare expenditures (5,6). However, the economic benefits of depression
treatment among cancer survivors with newly-diagnosed depression are yet to be established.
Therefore, the third aim of this study was to investigate the relationship between depression
treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with
newly-diagnosed depression and incident breast, colorectal or prostate cancer.
The findings indicated that depression treatment during the six months after depression
diagnosis increased short-term healthcare expenditures. Even after adjustment for observed and
unobserved selection bias, the positive association between depression treatment and short-term
healthcare expenditures persisted. This finding was robust using different model specifications.

5.2 Implications of the Findings
5.2.1 Clinical Implications
The findings from the current dissertation suggests that oncologists and other healthcare
providers need to provide routine screening for depression especially for individuals who are
diagnosed with colorectal cancer and those diagnosed at an advanced stage at cancer diagnosis.
Such screening for depression after cancer diagnosis is important to detect depression and treat it
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before it becomes severe. In addition, the study findings indicate that detection and treatment of
depression can be enhanced by visiting primary care providers, suggesting that oncologists can
play an important role by ensuring that cancer survivors continue visiting their primary care
providers.
As competing demands to treat cancer may impede the management of depression,
oncologists and other healthcare providers may need to recognize that ongoing cancer treatment
should not delay the management of depression as early depression treatment can improve not
only depression but also cancer clinical outcomes. However, our study findings suggest that
receiving depression treatment alone may not be sufficient to improve the economic outcomes of
cancer survivors in usual care setting. Therefore, integrated coordinated care for depression
which provides treatment, assessment of response and monitoring adherence to depression
treatment may be needed to improve depressive symptoms which in turn can improve the
economic outcomes of cancer survivors.

5.2.2 Policy Implications
Recognition and treatment of depression are critical cancer care priorities. The findings
from the current study highlights the need for practice and policy measures to increase the
screening for depression in cancer survivors with high risk of newly-diagnosed depression. Such
screening can help in early detection and early management of depression. There is a vital need
to reduce racial disparities in receiving depression treatment. African-Americans simply do not
have the same receive antidepressants relative to white Americans, whether due to access to care,
cultural or economic factors. Further, the management of depression depends very much on the
availability of psychologists to provide psychotherapy treatment and insufficient supply of
psychologists can impede the provision of evidence based depression treatment. Therefore, there
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is a need for policy measures to reduce racial disparities and improve the supply of mental
healthcare providers.
The current study suggests that depression treatment is associated with an increase in
healthcare expenditures. Such findings have implications for the Accountable Health
Organization (ACOs) Medicare Shared Saving Program expenditures benchmarking and the new
payment models’ “bundled payment” (3). Under the ACOs, healthcare expenditure estimates can
be used for risk adjustment while setting the expected expenditures benchmark for individuals
with cancer and depression who received depression treatment. In addition, it can help the new
payment models in setting the quality metrics that providers must achieve to maximize their
payment or for setting the prospective payment for the episode of care provided for cancer
patients who received depression treatment.

5.3 Unique Contributions of the Study
This is the first study that has investigated the variations in the risk of newly-diagnosed
depression among elderly with incident breast, colorectal or prostate cancer and identified cancer
types with high risk of newly-diagnosed depression. This study’s findings are therefore
significant since the risk of depression in cancer survivors has, until now, always been compared
to matched non-cancer cohorts. This study fills this gap. Furthermore, the current study focused
on depression treatment received after depression diagnosis. Although previous studies have
estimated depression treatment rates among cancer survivors, all of them have examined
prevalent depression treatment, which can be before or after depression diagnosis (4,5). This
study identified many barriers to receive depression treatment which have not been considered in
the previous studies such as cancer treatment and availability of mental healthcare providers.
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Moreover, this dissertation provides a knowledge base on the association between depression
treatment on short-term healthcare expenditures among cancer survivors. Previous studies among
cancer survivors focused mainly on how depression increases healthcare expenditures, but none
of the previous studies investigated whether depression treatment itself can lead to cost savings
or not.
5.4 Strengths
The current study has many strengths related to the data sources used and the study
design. This study used the most recent available SEER-Medicare data for years 2007 to 2012.
This data enabled us to use a cohort study design and follow a large number of individuals to
identify newly-diagnosed depression after cancer diagnosis. Also, the availability of a
prescription drugs in the SEER-Medicare database enabled us to identify depression treatment
after depression diagnoses in a real world setting. Further, this study controlled for many
variables that affect the risk of depression and the treatment of depression, such as cancer stage
and cancer treatment. Finally, to control for observable and non-observable selection bias this
study used the inverse probability weighting technique (IPTW) and the instrumental variable
approach.
5.5 Limitations
Depression diagnosis may be under-coded in claims data, so this study may have
underestimated the risk of depression. Additionally, the antidepressants were identified from
claims, so it is not certain if they were actually used. This study cannot exclude misclassification
bias; individuals who may have received depression treatment in inpatient and emergency
department settings and had no claims, were considered as receiving no depression treatment.
This study cannot eliminate observable and non-observable selection biases, although the inverse
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probability weighting technique and the instrumental variable technique were used to control for
these biases. Further, claims data do not provide information about the severity of depression,
pain and fatigue, body mass index, attitude, or preferences, which can affect the risk of
depression and its treatment. The study findings are not generalizable as the study population is
restricted to those residing in SEER regions, to those with fee-for-service Medicare plans, and to
those with breast, colorectal and prostate cancer.
Despite these limitations, this study provides a knowledge base on the risk of newly
diagnosed depression after cancer diagnosis, on depression treatment rates and factors affecting
depression treatment and on the impact of depression treatment on economic outcomes among
elderly Medicare beneficiaries with incident breast, colorectal or prostate cancer.

5.6 Suggestions for Future Research
This study identified some unanswered questions that need further investigation in future
research. As the focus of this study was on the most common types of cancer, future studies may
need to investigate the risk of newly-diagnosed depression and depression treatment rates among
elderly with other types of cancer. As the current study found that one-quarter of the individuals
with depression did not receive any depression treatment, there is a need to explore the reasons
why so many patients are not receiving therapy and to investigate if these individuals are
receiving alternative therapy. In addition, as the findings of this study unexpectedly indicated
that depression treatment increased short-term healthcare expenditures, there is a need to
investigate whether or not adherence or adequacy of depression treatment can lead to cost
savings. Future studies may need to explore the relationship between depression treatment and
healthcare expenditures among Medicare providers who have been designated as PCMH
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providers because PCMH has all the features of a collaborative care model for depression
treatment.
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Appendix A. Codes Related to Cancer Diagnosis and Treatment
Cancer Diagnosis and Treatment
ICD-9-CM Codes
Siter-WHO recodes

ICD-9-CM
Procedure Codes

HCPCS/CPT Codes

Breast Cancer

8520-8529, 85338536, 8540-8548

19120, 19125, 9126,
19300-19307,

Colorectal Cancer

4530-4534, 45414543, 4549, 45504552, 4561-4563,
4570-4576, 4579,
4580-4583, 45904595, 4601, 4603,
4604, 4610, 4611,
4613, 4614, 46204623, 4835,48404843, 4849-4852,
'4859-4865, 4869

44140, 44141, 414344147, 4150, 44160,
44204-44208, 415044153, 44155, 4158,
44210-44212, 5160,
45170, 45171, 511045114, 45116, 511945121, 45123, 5126,
45395, 45397

Prostate Cancer

602-606

55801, 55810, 5812,
55815, 5821,55831,
55840, 55842, 5845,
55866

9925, 9928

96401- 96549, Q0083Q0085, J9000-J9999,
S9329-S9331, J85018999, J0640

0331, 0332,
0335

9220-9239

77261-77799, C1715C1720, C2634-C2699,
C1728

0330, 0333

Breast Cancer

26000

Colorectal Cancer

21041 , 21042, 21043,
21044, 21045, 21046,
21047, 21048, 21049,
21051, 21052

Prostate Cancer

28010

Revenue
Center
Codes

Cancer Treatment - Surgery

Cancer Treatment - Chemotherapy
V581, V662, V672

Cancer Treatment - Radiation Therapy
V580, V661, V671
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